US20040030368A1 - Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa - Google Patents
Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa Download PDFInfo
- Publication number
- US20040030368A1 US20040030368A1 US10/440,690 US44069003A US2004030368A1 US 20040030368 A1 US20040030368 A1 US 20040030368A1 US 44069003 A US44069003 A US 44069003A US 2004030368 A1 US2004030368 A1 US 2004030368A1
- Authority
- US
- United States
- Prior art keywords
- light
- light source
- patient interface
- phototherapeutical
- high intensity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000003463 hyperproliferative effect Effects 0.000 title claims abstract description 20
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 11
- 210000002850 nasal mucosa Anatomy 0.000 title description 9
- 230000003287 optical effect Effects 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 31
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 13
- 201000009890 sinusitis Diseases 0.000 claims abstract description 13
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 12
- 230000002165 photosensitisation Effects 0.000 claims abstract description 5
- 208000024891 symptom Diseases 0.000 claims description 48
- 210000004400 mucous membrane Anatomy 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 36
- 201000010105 allergic rhinitis Diseases 0.000 claims description 16
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 14
- 210000003695 paranasal sinus Anatomy 0.000 claims description 14
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000010453 quartz Substances 0.000 claims description 10
- 208000001319 vasomotor rhinitis Diseases 0.000 claims description 10
- 208000000592 Nasal Polyps Diseases 0.000 claims description 9
- 230000000172 allergic effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 8
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 7
- 206010068957 Eosinophilic rhinitis Diseases 0.000 claims description 7
- 206010015150 Erythema Diseases 0.000 claims description 7
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 7
- 229910052724 xenon Inorganic materials 0.000 claims description 7
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- QIFOFCWBJPAXTM-UHFFFAOYSA-N chembl375232 Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CN=CC=1)=C1C=CC(=N1)C(C=1C=CN=CC=1)=C1C=CC(N1)=C1C=2C=CN=CC=2)=C2N=C1C=C2 QIFOFCWBJPAXTM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 239000003365 glass fiber Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 206010039083 rhinitis Diseases 0.000 abstract description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 22
- 238000001126 phototherapy Methods 0.000 description 15
- 238000002428 photodynamic therapy Methods 0.000 description 13
- 210000003128 head Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000001429 visible spectrum Methods 0.000 description 7
- 206010028748 Nasal obstruction Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003254 palate Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010039094 Rhinitis perennial Diseases 0.000 description 3
- 208000036284 Rhinitis seasonal Diseases 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 3
- 229940115057 methyl 5-aminolevulinate Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- HGCGQDMQKGRJNO-UHFFFAOYSA-N xenon monochloride Chemical compound [Xe]Cl HGCGQDMQKGRJNO-UHFFFAOYSA-N 0.000 description 3
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010052437 Nasal discomfort Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940125379 topical corticosteroid Drugs 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VSQYNPJPULBZKU-UHFFFAOYSA-N mercury xenon Chemical compound [Xe].[Hg] VSQYNPJPULBZKU-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0605—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0606—Mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0607—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0608—Rectum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0609—Stomach and/or esophagus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0611—Vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Definitions
- the present invention relates to the treatment and prevention of inflammatory and hyperproliferative diseases of body cavities, more particularly to the treatment and prevention of diseases of the nasal cavity by phototherapeutical methods.
- Rhinitis is an inflammatory disorder of the nasal mucous membrane, which is characterized by nasal itch, sneeze, nose running, nasal blockage, and rarely by loss of smelling.
- the inflammation of the nasal mucous membrane is frequently associated with the inflammation of the paranasal sinuses (rhinosinusitis, chronic sinusitis).
- rhinosinusitis chronic sinusitis
- polyps develop on the mucous membrane.
- the allergic rhinitis is the most frequent allergic disease affecting 10-20% of the population.
- the number of patients with allergic rhinitis, especially in the well developed industrial countries increased very rapidly in the last few years. Because of the high number of patients the direct and indirect costs of this disease are great.
- Hay fever Although hay fever is not a very severe disease, its unpleasant symptoms worsen the quality of life considerably. Hay fever is frequently associated with allergic conjunctivitis and sometimes with general symptoms. The symptoms last only for a few months in some patients (seasonal rhinitis), while in others they last the whole year (perennial rhinitis).
- the symptoms of the allergic diseases develop as follows.
- An allergen enters the body and induces the production of a specific IgE, which binds to specific receptors on the surface of mast cells. After subsequent exposure the allergen crosslinks the IgE receptors, resulting in mediator release from the mast cells. These mediators are responsible for the development of the symptoms in patient.
- a further characteristic disease is vasomotor rhinitis.
- Vasomotor rhinitis is an inflammatory disorder of the nasal mucous membrane with unknown origin. The clinical symptoms are largely similar to that of allergic rhinitis: permanent nasal blockage, nasal itch, sneeze, nose running, and rarely loss of smelling. Mastocyte-activating mediators cause the symptoms. These are released from the nerve endings of the nasal mucous membrane upon irritation.
- a further characteristic disease is the nonallergic eosinophilic rhinitis.
- This disease is characterized by the high number of eosinophils in the nasal secretions and by the lack of an allergic origin.
- the disease is frequently associated with the development of nasal polyps, the hyperproliferative condition of the nasal mucous membrane. The clinical symptoms are the same as in allergic rhinitis.
- Additional diseases are rhinosinusitis and sinusitis.
- the inflammation of the paranasal sinuses is frequently associated with the inflammatory condition of the nasal mucous membrane (nasosinusitis).
- the isolated inflammation of the paranasal sinuses is also a frequent disease (sinusitis). This disease has often an allergic origin, although its exact cause remains unknown. There is no well-tested treatment, thus usually the same therapy is used as for rhinitis.
- UVB light 280 nm-320 nm
- ultraviolet-A light 320 nm-400 nm
- the ultraviolet light inhibits the antigen-induced cellular immune response and is able to induce tolerance (Streilein J W, Bergstresser P R: Genetic basis of ultraviolet-B on contact hypersensitivity. Immunogenetics 27: 252-258, 1988).
- the ultraviolet light suppresses the immune reaction by inhibiting the antigen presentation and by inducing T-cell apoptosis. Irradiation of the skin with ultraviolet-B light or ultraviolet-A light on an area previously photosensitized by psoralen is known to inhibit the immunological processes in the skin. For the treatment of skin diseases there are a number of phototherapeutical devices available.
- These phototherapeutical devices include ultraviolet light sources. These light sources might be classified based on, for example, their operational principle, output energy or power, mode of operation (impulse or continuous), and whether they are emitting monochromatic or multiwavelength light.
- BB-UVB broad band ultraviolet B
- NB-UVB narrow band ultraviolet B
- Phototherapeutical treatments improved significantly with the appearance of ultraviolet light delivering optical systems.
- Such an ultraviolet light delivering phototherapeutical system with fiber optic is used in the Saalmann Cup instrument, in which the concentrated ultraviolet light is coupled into a fiber optic cable. Therefore, it is suitable for the treatment of smaller lesions of the skin or mucous membrane (Taube K M, Fiedler H: Hochkonzentrtechnisch UV Bestrahlungnies Hautbezirke mit einadmi ceremonistrahler. Unen und klinischeMech.
- the Saalmann Cup can not be introduced into smaller body cavities because of its large contact area and because of the thickness of the used fiber optic cable.
- This device can be used in body cavities where the distal end of the fiber optic cable and the area to be treated can be visually controlled, such as the oral cavity. For this reason, this device is unsuitable for the treatment of body areas, which cannot be visually controlled, such as the nasal and paranasal mucous membrane, the gastrointestinal, and the urogenital mucous membrane.
- Neuman and Finkelstein used narrow-band, low energy, red-light phototherapy for the treatment of the nasal mucous membrane and they found it effective for perennial allergic rhinitis but not for nasal polyposis (Neuman I., Finkelstein Y. Narrow-band red light phototherapy in perennial allergic rhinitis and nasal polyposis. Ann Allergy Asthma Immunol 78: 399-406, 1997).
- Neumann and Finkelstein irradiated the nasal mucosa using a 660 nm light emitting diode (LED) with a dose of 3 J/nostril day. They referred to their treatment as “a low-energy stimulation” as they used a 4 mW light emitting diode.
- LED light emitting diode
- a low-energy stimulation As the total surface of the mucosa of one nostril is approximately 15 cm 2 , the nasal mucosa was illuminated with a total daily dose of approximately 0.2 J/cm 2 .
- the photodynamic therapy has been used for the last hundred years for the treatment of cancers. Many studies confirmed the efficacy of PDT for the treatment of different tumors in the last 30 years.
- 5-aminolevulinate ALA
- ALA is applied into the area to be treated.
- ALA is converted in situ into the active endogenous photosensitizer protoporphyrin IX, which sensitizes the hyperproliferative cells. Illumination of the lesions with high intensity visible light results in the production of singlet oxygen molecules, the presence of which causing the subsequent death of the sensitized cells.
- the light of the 308 nm xenon chloride excimer laser can be guided by fiber optic cable for the cleaning of root canals by ablation (Folwaczny M, Mehl A, Haffaer C, Hickel R: Substance removal on teeth with and without calculus using 308 nm XeCl excimer laser radiation. An in vitro investigation. J. Clin. Periodontol 26: 306-12, 1999).
- the 308 nm xenon chloride excimer laser is also suitable to treat artherosclerosis by treating the blood vessel walls (U.S. Pat. No.
- Phototherapeutical systems attached to endoscopes are also used for the photodynamic treatment of tumors, such as bladder carcinoma or bronchial cancer.
- tumors such as bladder carcinoma or bronchial cancer.
- these instruments have special distal ends for tumor treatment (U.S. Pat. Nos. 4,313,431; 4,612,938; 4,676,231; 4,998,930; 5,146,917).
- the phototherapeutical systems delivering light consist of a hand piece specifically shaped to a specific treatment. As such, they are either unsuitable or inconvenient for the treatment of small body cavities such as the nasal cavity with visual control.
- a phototherapeutical apparatus including: a light source, operable to generate high intensity visible light, an optical guidance system, operable to receive and guide the high intensity visible light of the light source, and a patient interface, operable to receive the guided light from the optical guidance system, wherein the patient interface is operable to apply the guided light to a tissue surface of a nasal cavity.
- the patient interface is insertable at least partially into a nasal cavity.
- the method includes providing a phototherapeutical apparatus, which includes a light source, operable to generate high intensity visible light, an optical guidance system, coupled to the light source, and a patient interface, coupled to the optical guidance system.
- the method further includes preparing for the application of the phototherapeutical apparatus, inserting at least partially the patient interface into a nasal cavity, generating high intensity visible light with the light source, coupling the high intensity visible light into the patient interface through the optical guidance system, and applying the high intensity visible light by the patient interface to a tissue surface of the nasal cavity, wherein the tissue of the nasal cavity has an inflammatory disease or a hyperproliferative disease.
- Examples of inflammatory diseases include the inflammatory diseases of the nasal cavity. Research showed that single or repeated irradiation of the nasal mucous membrane and paranasal sinuses with high intensity visible light, or with a combination of visible light with ultraviolet light (of the UVB or UVA type, or both) suppress the clinical symptoms of rhinitis, sinusitis, and rhinosinusitis, and result the regression of nasal polyps.
- photodynamic therapeutical methods are included, where a photosensitizing substance, such as deltaaminolevolunic acid is applied to the tissue surface before irradiation with light.
- a photosensitizing substance such as deltaaminolevolunic acid
- the phototherapeutical apparatus is also effective for the prevention of inflammatory diseases or hyperproliferative diseases.
- phototherapy is applied before the appearance of clinical symptoms of the disease.
- FIG. 1 illustrates an embodiment of the phototherapeutical apparatus according to the invention.
- FIGS. 2 A-B illustrate exemplary implementations of the light source and the phototherapeutical apparatus according to an embodiment of the invention.
- FIG. 3 illustrates an exemplary implementation of the optical coupling unit according to an embodiment of the invention.
- FIG. 4 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 5 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 6 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 7 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 8 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 9 illustrates a phototherapeutical apparatus including a flexible endoscope, according to an embodiment of the invention.
- FIG. 10 illustrates steps of the phototherapeutical method, according to an embodiment of the invention.
- FIG. 11 illustrates the decrease of clinical symptoms due to treatment with an embodiment of the phototherapeutical method, according to an embodiment of the invention.
- FIG. 12 illustrates the decrease of clinical symptoms due to treatment with an embodiment of the photodynamic therapeutical method, according to an embodiment of the invention.
- FIGS. 1 - 12 of the drawings Like numerals are used for like and corresponding parts of the various drawings.
- the phototherapeutical apparatus is suited for the treatment and prevention of common inflammatory diseases of the body.
- the phototherapeutical apparatus is used for the treatment and prevention of the diseases of a nasal mucous membrane and paranasal sinuses such as allergic rhinitis (hay fever), vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis (inflammation in the paranasal sinuses), or nasal polyps.
- Some embodiments of the phototherapeutical apparatus utilize visible light. Some embodiments utilize a combination of visible light and ultraviolet light. Some embodiments utilize high intensity light.
- FIG. 1 illustrates a phototherapeutical apparatus 100 , according to an embodiment of the invention.
- Phototherapeutical apparatus 100 includes a light source 1 .
- Light source 1 is operable to generate a light beam 2 of visible light, ultraviolet light, or a combination of visible and ultraviolet light.
- Light source 1 is operable to generate high intensity light.
- Light beam 2 enters into an optical coupling unit 3 , where light beam 2 is focused.
- the focused light beam is coupled by optical coupling unit 3 into an optical guidance system 4 .
- Optical guidance system 4 guides the focused light beam into a patient interface 5 .
- Patient interface 5 is insertable at least partially into a body cavity, where it applies the light beam to a tissue surface of a body cavity.
- FIG. 1 illustrates an embodiment, where the body cavity is the nasal cavity and the patient interface is inserted through a nostril 6 .
- light source 1 generates a continuous light beam, in others a slowly oscillating light beam.
- the frequency of oscillations can be below about 100 Hertz.
- the continuous light beam and slowly oscillating light beam will be jointly referred to as quasi-continuous light beam.
- Light source 1 can be, for example, a monochromatic light source or a multiwavelength light source.
- a variety of monochromatic light sources such as lasers, can be used as light source 1 .
- Examples include any type of diode lasers or other lasers emitting high intensity light in the visible spectrum.
- a variety of multiwavelength light sources can be used as light source 1 . Examples include electric discharge lamps, arc lamps filled with xenon, mercury vapour, xenon and mercury vapour, fluorescent lamps, and light emitting diodes (LEDs).
- substantially all of the light, generated by light source 1 is visible light, i.e. it has a wavelength in the visible spectrum, between about 400 nm and about 700 nm. In some embodiments the wavelength is in the high energy portion of the visible spectrum, between about 400 nm and about 600 nm.
- the generated visible light has a dose up to about 100 J/cm 2 on the targeted tissue.
- light beams with a dose between about 10 J/cm 2 and about 100 J/cm 2 will be referred to as high intensity light.
- the range of the dose of the light may depend on the specific patient. For some patients a light with a dose of, for example 4 J/cm 2 or 7 J/cm 2 may be already high intensity.
- light source 1 generates a certain amount of ultraviolet light simultaneously with the visible light.
- the ultraviolet light can have a wavelength in the ultraviolet-B (280 nm-320 nm) and ultraviolet-A (320 nm-400 nm) part of the spectrum.
- FIG. 2A illustrates an example of light source 1 , operable to generate visible light, ultraviolet light, or a combination of visible and ultraviolet light, according to embodiments of the invention.
- An electric power supply unit 7 is connected to electrodes 11 by wires 8 . Electrodes 11 enter the internal space of quartz bulb 12 , which is filled with gas. The electric power, provided by electric power supply 7 causes an electric discharge in the gas. During this discharge light is generated. The wavelength of the light depends, among others, on the chemical composition of the gas. With a suitable choice of the chemical composition of the gas the generated light will have a wavelength in the visible spectrum or in the ultraviolet spectrum.
- the gas or gas mixture in quartz bulb 12 can include xenon, argon, and mercury vapor, and any other gas that emit light substantially in the visible spectrum, possibly with a portion emitted in the ultraviolet spectrum.
- Other portions of the generated light propagate in other directions. Part of these portions are reflected by concave mirror 9 toward focusing lens 15 .
- Focusing lens 15 focuses all incoming light efficiently into a light beam 2 .
- the focused light beam 2 leaves housing 10 through an output opening 14 and reaches an optical filter 13 .
- optical filter 13 transmits visible light, ultraviolet A, or ultraviolet B, or any combination of light. From optical filter 13 the filtered and focused light beam 2 is coupled into an optical guidance system 4 .
- the volume of the discharge space in quartz bulb 12 varies in the range of about 1 mm 3 to about 0.1 mm 3 .
- the discharge space is positioned approximately in the focus of concave mirror 9 , so concave mirror 9 can efficiently focus the emitted light onto focusing lens 15 .
- FIG. 2B illustrates a phototherapeutical apparatus 100 , according to a related embodiment of the invention.
- Power supply 7 provides adjustable power for apparatus 100 .
- Power supply 7 may include a medical grade isolation transformer. The isolation transformer also provides protection from electrical shock.
- Quartz bulb 12 is operable to generate light with a wavelength between about 280 nm and about 700 nm. In some embodiments quartz bulb 12 is operable to generate light with a wavelength between about 280 nm and about 600 nm.
- An embodiment of quartz bulb 12 is an electric microdischarge lamp. In embodiments the length of discharge space, or “arc”, is between about 1 mm and about 10 mm. Because of the smallness of the discharge volume it is easy to collect the generated light and to couple it into optical guidance system 4 . As an example, an electric micro-discharge lamp with a power of about 35 watts may output between about 0.1 watts to about 2 watts at patient interface 5 .
- Previous examples of arc lamps include mercury and mercury xenon lamps, described, for example, by Hartmann et al. in Patent Application WO 02/13905. In these lamps the discharge space is bigger. Accordingly, these lamps need a power of 500 to 1500 watts to output 2 to 4 watts at patient interface 5 .
- embodiments of the present invention utilize micro-discharge lamps. These substantially smaller discharge lamps can operate with a power of about 35 watts. Micro-discharge lamps also produce much less heat. Therefore, in some embodiments no ventilation is necessary to cool the micro-discharge lamp during usage. Because of the small lamp size some embodiments of the phototherapeutical device are portable. For example, embodiments of the device can be powered through the cigar lighter of an automobile.
- the generated light beam 2 is coupled by optical coupling unit 3 into optical guidance system 4 .
- Optical coupling unit 3 includes optical filter 13 and beam shutter 110 .
- Optical filter 13 is operable to select a range of wavelengths from the overall wavelength range of light beam 2 .
- Commercially available optical filters 13 include SCHOTT GG 400 (manufactured by Schott A. G., Germany), which is operable to filter out the ultraviolet portion of light beam 2 with wavelengths below about 400 nm.
- Optical filter SCHOTT WG 320 (Schott A. G., Germany) is operable to filter out the ultraviolet-B portion of the spectrum, below about 320 nm.
- Beam shutter 10 is controlled and monitored by a control panel 106 .
- Control panel 106 may include an electronic timing unit, which is operable to log the operational ON time of power supply 7 .
- the intensity of light beam 2 is adjustable by controlling the current output of power supply 7 .
- Phototherapeutical apparatus 100 can be pre-programmed through control panel 106 . Pre-programming may include selecting a treatment irradiant dosage by setting the timing unit and adjusting the intensity of light beam 2 by setting the current of power supply 7 .
- Some embodiments may include a footswitch 104 . Footswitch 104 can be used to convenient application of apparatus 100 . For example, footswitch can be used to start a pre-programmed application of apparatus 100 .
- Light beam 2 is coupled by optical coupling unit 3 into optical guidance system 4 .
- Optical guidance system 4 might provide additional optical filtering.
- Embodiments of optical guidance system 4 include an optical cable with a core diameter between about 1 mm and about 10 mm.
- Optical guidance system 4 couples light beam 2 into patient interface 5 .
- Patient interface 5 may be inserted into the nasal cavity of a patient.
- FIG. 2B shows a hollow plastic tip as a patient interface 5 .
- Patient interface 5 might also provide additional optical filtering.
- Patient interface 5 may include a tip which transmits visible light but does not transmit ultraviolet light, or a tip which transmits both visible and ultraviolet light.
- FIG. 3 illustrates an embodiment of optical coupling 3 .
- Light beam 2 entering optical coupling unit 3 is directed by a dichroic mirror 16 into optical guidance system 4 through a lens system 17 .
- Dichroic mirror 16 simultaneously performs a spectral filtering of light beam 2 .
- optical guidance system 4 is also applicable to guide back reflected light, reflected from the site of application.
- the light emerging from the site of the application passes dichroic mirror 16 and can be detected through an observing optical device 19 to assist the application of the phototerapeutical device.
- Optical guidance system 4 can be, for example, an optical cable or arm suitable to guide light.
- the optical cable or arm can be formed of any one of a large number of known suitable materials, among others quartz glass or capillary tubes filled with a liquid capable of guiding light, wherein the internal surface of the capillary tubes are covered with ultraviolet reflecting material.
- the diameter of the optical cable can be between about 1 micron and about 10 mm.
- optical guidance system 4 also performs a spectral filtering of light beam 2 .
- FIG. 4 illustrates an embodiment of patient interface 5 , suitable for the treatment of the nasal mucous membrane and paranasal sinuses.
- Patient interface 5 is suited to be positioned at least partially in the nostril or nasal cavity of a patient and guide light beam 2 onto the tissue surface to be treated.
- Many variations of patient interface 5 can be constructed and are meant to be within the scope of the invention.
- optical guidance system 4 is attached to handgrip 20 .
- the guided light enters from optical guidance system 4 through handgrip 20 into optical tube 22 and propagates into a tapered end piece 24 .
- a head 25 of patient interface 5 is coupled to optical tube 22 by a fastener 23 .
- a scanning light source 27 is included to illuminate the area of the tissue surface to be treated. Scanning light source 27 is built into handgrip 20 and can be powered by either an internal or an external power supply unit.
- Mirror 28 reflects the scanning light of scanning light source 27 onto the tissue surface to be treated. Light beam 2 and the scanning light propagate through output opening 26 onto the tissue surface to be treated.
- the end of patient interface 5 where light beam 2 leaves patient interface 5 is sometimes referred to as the distal end.
- the distal end is where output opening 26 is positioned.
- a magnifying glass 21 mounted onto patient interface 5 provides visual control of the application of the light of phototherapeutical apparatus 100 .
- FIG. 5 shows another embodiment of patient interface 5 , wherein the light beam 2 enters from optical guidance system 4 through a lens 29 of handgrip 20 .
- Light beam 2 is then reflected on dichroic mirror 16 , which is mounted inside optical tube 22 , and leaves patient interface 5 through output opening 26 of head 25 .
- scanning light source 27 is mounted inside handgrip 20 . The scanning light passes through dichroic mirror 16 and is reflected by concave holed mirror 30 to illuminate the tissue surface to be treated.
- external scanning light sources are applied to illuminate the tissue area to be treated.
- FIG. 6 illustrates another embodiment of patient interface 5 .
- optical guidance system 4 is coupled into a pen-shaped handgrip 31 .
- Light beam 2 enters pen-shaped hand grip 31 and is reflected by flat surface treating head 32 .
- Flat surface treating head can include, among others, a quartz prism or a flat mirror.
- Flat surface treating head 32 is coupled to pen-shaped handle 31 with a fastener 23 .
- FIG. 7 illustrates another embodiment of patient interface 5 , which is suitable for the circular treatment of a body cavity, for example, the nasal cavity.
- optical guidance system 4 guides light beam 2 into pen-shaped grip 31 , where it is reflected by circular reflector 33 in a circular manner.
- Circular reflector 33 can be, for example, a conical or a spherical reflecting surface.
- Circular applicator head 34 housing circular reflector 33 , is coupled to pen-shaped handle 31 with fastener 23 .
- Body cavities, such as the nasal cavity can be treated with this embodiment in a circular manner.
- FIG. 8 illustrates another embodiment of patient interface 5 , which is suited for a spot treatment of tissue surfaces, such as the nasal mucous membrane.
- Optical guidance system 4 guides light beam 2 into pen-shaped handle 31 , where it is guided onto a spot on the tissue to be treated by spot applicator 36 .
- Spot applicator 36 can be, for example, a plano-parallel disk or a lens 36 made of quartz or plastic transparent to light.
- Spot applicator 36 is housed by spot applicator head 35 , which is fastened onto pen-shaped handle 31 by a fastener 23 .
- FIG. 9 illustrates another embodiment of patient interface 5 , which is suited for a spot treatment of tissue surfaces, such as the nasal mucous membrane.
- Light beam 2 generated by light source 1 is focused and coupled by optical coupling unit 3 into optical guidance system 4 .
- Optical guidance system is integrated into flexible endoscope 37 .
- Flexible endoscope 37 is capped with patient interface 5 .
- Patient interface 5 includes a spot applicator 36 .
- Spot applicator 36 can be, for example, a plano-parallel disk or a lens 36 made of quartz or plastic transparent to light. In some embodiments spot applicator 36 can have a sloped distal end.
- a scanning light is provided by scanning light source 27 .
- the generated scanning light is guided through lens 41 into scanning optical cable 42 .
- Scanning optical cable 42 can be also integrated into flexible endoscope 37 .
- the scanning light illuminates the tissue surface to be treated through patient interface 5 .
- Image processing optical cable 38 which can be integrated into flexible endoscope 37 as well.
- Image processing optical cable 38 is coupled into image processing unit 39 to facilitate visual control of the application of the phototerapeutical apparatus.
- optical guidance system 4 can be rotated within flexible endoscope 37 by positioning unit 40 , so that the direction of light beam 2 emitted through patient interface 5 can be modified.
- flexible endoscope 37 itself can be rotated by positioning unit 40 .
- Some embodiments for the circular and the spot treatment of tissue surfaces may include a Panoramic Annular Lens (PAL) optical system.
- PAL Panoramic Annular Lens
- a PAL system, transparent to the light can be included into circular applicator head 34 and spot applicator head 35 .
- Including a PAL optical system can be helpful for simultaneous treatment of tissue surfaces and optical image processing.
- a phototherapeutical method 200 for the treatment and prevention of inflammatory and hyperproliferative diseases of body cavities, more particularly for the treatment and prevention of common inflammatory diseases of the nasal mucous membrane and paranasal sinuses, including allergic rhinitis (hay fever), vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis (inflammation in the paranasal sinuses), and for the treatment and prevention of hyperproliferative diseases, including nasal polyps (a frequent benign hyperproliferative lesion in chronic inflammatory conditions of the nasal mucous membrane).
- allergic rhinitis hay fever
- vasomotor rhinitis nonallergic eosinophilic rhinitis
- chronic sinusitis inflammation in the paranasal sinuses
- hyperproliferative diseases including nasal polyps (a frequent benign hyperproliferative lesion in chronic inflammatory conditions of the nasal mucous membrane).
- Phototherapeutical method 200 is based on the inventor's research results, which showed that the application of visible light, or a combination of visible and ultraviolet light to tissue surfaces in the nasal cavity decreases the number and the activity of inflammatory cells (mast cells, eosinophils, and lymphocytes) responsible for the mediator release and synthesis in the mucous membrane, and thereby it reduces the clinical symptoms of inflammatory, hyperproliferative, and allergic diseases.
- inflammatory cells mast cells, eosinophils, and lymphocytes
- FIG. 10 illustrates steps of phototherapeutical method 200 .
- phototherapeutical apparatus 100 includes: light source 1 , optical guidance system 4 , coupled to light source 1 , and patient interface 5 , coupled to optical guidance system 4 .
- Phototherapeutical method 200 can be practiced with any embodiment of phototherapeutical apparatus 100 , described earlier.
- light source 1 is operable to generate high intensity visible light.
- High intensity light includes light with a dose between about 10 J/cm 2 and about 100 J/cm 2 .
- light source 1 generates visible light in the high energy portion of the spectrum, with wavelength between about 400 nm and about 600 nm.
- visible light is used alone, without combination with UV light, high intensity light achieves significant immunosuppression in the nasal mucosa.
- the present method of using high intensity visible light differs from other methods using low-intensity light emitting diodes. Some low intensity methods apply red light in a dose of about 0 . 2 J/cm 2 , therefore the present method applies light in orders of magnitude higher doses.
- photoherapeutical apparatus 100 include essentially monochromatic light sources, other embodiments include multiwavelength light sources.
- Embodiments with monochromatic light sources include, for example, any type of diode lasers, or any other lasers, which emit light in the visible spectrum.
- Multiple wavelengths embodiments include, for example, discharge lamps and arc lamps. Each of these lamps can be filled, for example, with xenon, mercury vapour, and a mixture of xenon and mercury vapour. Other embodiments include fluorescent lamps, light emitting diodes (LEDs), and dye lasers.
- LEDs light emitting diodes
- a preparation for the treatment by phototheraputical method 200 is performed.
- the preparation can include—in case of a combined visible and ultraviolet light treatment—determining a light threshold of the particular patient on a part of the patient's skin, which was not recently exposed to sunlight.
- One measure of a light threshold is the Minimal Erythema Dose (MED).
- MED Minimal Erythema Dose
- the MED is the smallest dose of combined light, which causes erythema on the patient's previously unexposed skin after 24 hours.
- the MED is then used to determine the value of the first dose, applied to the area to be treated.
- the preparation can further include treatment of the nasal mucosa with nasal decongestants to decrease the odema of the nasal mucosa in order to be able to illuminate larger mucosa surfaces.
- the preparation can further include selecting a suitable patient interface 5 for practicing phototherapeutical method 200 . This choice depends, for example, on the location of the area of the tissue surface to be treated and the anatomy of the body cavity of the patient.
- step 212 high intensity visible light beam 2 is generated by light source 1 .
- step 216 the generated high intensity visible light beam 2 is coupled into patient interface 5 through optical guidance system 4 .
- step 220 the generated high intensity visible light is applied by patient interface 5 to a tissue surface of a nasal cavity.
- step 220 includes inserting patient interface 5 at least partially into the nasal cavity. Patient interface 5 is inserted at the distal end.
- a high intensity visible light was applied through patient interface 5 with a dose between about 10 J/cm 2 and about 100 J/cm 2 .
- the treatment with such high intensity visible light can be repeated one or more times per week.
- the repeated application of such high intensity visible light can be performed with the same dose or with increasing doses, depending on the patient's tolerance and on the improvements of the clinical symptoms.
- the high intensity visible light was applied in a dose between about 10 J/cm 2 and about 100 J/cm 2 , in combination with ultraviolet-A light (320 nm-400 nm) in a dose between about 1 J/cm 2 and about 10 J/cm 2 , or ultraviolet-B light ( 295 - 320 nm) in a dose between about 0.01 J/cm 2 and about 1.0 J/cm 2 , or both.
- the high intensity visible light was the high energy portion of the visible spectrum, with wavelength between about 400 nm and about 600 nm.
- the previously determined MED value is used to determine the first dose, applied to the tissue surface to be treated.
- FIG. 11 illustrates the improvement of hay fever symptoms of the nasal mucous membrane as a result of being treated by phototherapeutic method 200 .
- the illustrated embodiment of method 200 used visible light (400 nm-700 nm) in high doses.
- the treatment included using the same dose four times per week. As shown, the clinical symptoms and complaints of the patients decreased significantly after the treatment.
- the preparation of step 206 includes increasing the efficacy of phototherapeutical method 200 by administering photosensitizing substances before the phototherapy with visible light.
- this method is referred to as photodynamic therapy (PDT).
- PDT photodynamic therapy
- Example for photosensitizing substances include porphirin precursors such as 5-aminolevulinate, or metabolites of porphirin precursors, or other synthetic porphirin precursors such as methyl 5-aminolevulinate. These materials can be used in concentrations between about 1% and about 20%.
- the preparation of step 206 includes increasing the efficacy of phototherapeutical method 200 by administering a combined high intensity visible light with ultraviolet light.
- a visible light is applied in combination with ultraviolet light
- the minimal erythema dosis (MED) can be measured on a part of the patient's skin, which was not exposed to sunlight before starting the therapy.
- the MED is the smallest ultraviolet dose, which induces erythema on a previously unexposed skin after 24 hours.
- step 220 the high intensity visible light in combination with ultraviolet light is applied to the nasal mucous membrane.
- the application can be started with a dose about 1.0 ⁇ MED to about 2.0 ⁇ MED, depending on the severity of the symptoms of the patient. During repeated applications in some embodiments the dose remains approximately constant. In other embodiments the dose is increased depending on the patient's tolerance. Step 220 can be repeated once or several times per week. Research showed that phototherapy inhibits rapidly and effectively the clinical symptoms of hay fever, including nasal blockage, nasal itch, nose running, sneezing and itching of the palate.
- FIG. 12 illustrates the improvement of hay fever symptoms of the nasal mucous membrane as a result of being treated by the combined visible/ultraviolet phototherapeutic method 200 .
- light source 1 is an electric discharge lamp, emitting more than 98% of its power with wavelength between about 320 nm and about 650 nm and approximately 2% of its power with wavelength between about 295 nm and 320 nm.
- Phototherapeutical method 200 is also suitable for the prevention of inflammatory and hyperproliferative diseases of nasal cavities.
- phototherapeutical method 200 can be started before the appearance of the clinical symptoms.
- phototherapeutical method 200 with photochemotherapy is also suitable for the prevention of the clinical symptoms of patients with seasonal allergic rhinitis.
- the treatment can be started before the appearance of the symptoms.
- the treatment can be administered once or several times per week depending on the tolerance of the patient.
- phototherapeutical method 200 is significantly cheaper than presently practiced drug based treatments.
- the ultraviolet light might facilitate the appearance of viral and bacterial infections on the treated areas because of its immunosuppressive effect. This effect is similar to the effect of topical corticosteroides. However, the likelihood for these infections is lower than that of the presently used local immuno-suppressive preparations, because light also has a direct microbicidal effect (Folwaczny M, Liesenhoff T, Lehn N, Horch H H: Bactericidal action of 308 nm excimer-laser radiation: an in vitro investigation. J Endodontics, 24: 781-785, 1998).
- the complete time of a treatment was 15 minutes and the treatment did not cause any complaint by the patient.
- the treatment was then repeated three times per week using the same phototherapeutical apparatus, but the irradiation dose was increased by 20% each occasion.
- the symptoms and complaints of the patient decreased to a large extent and in the third week after the nine treatment the patient was completely free of symptoms.
- the treatment was stopped and no recurrence was observed.
- the patient found this type of therapy to be more efficacious as compared to the previously used therapies.
- a patient with severe hay fever due to ragweed allergy did not impove under conventional therapy with antihistamines and corticosteroids. Therefore, an embodiment of phototherapeutical method 200 was administered.
- a special light source 1 was used to generate ultraviolet and high intensity visible light.
- the intensity of the light at the output end of patient interface 5 was 700 mW/cm 2 .
- the UVB (300-320 nm wavelengths) content of light beam 2 was 1%, the UVA (320 nm-400 nm) content was 13%, and the remaining 84% was in the visible (400-650 nm) portion of the spectrum.
- the minimal erythema dosage was first determined on the forearm of the patient not exposed to sunlight earlier, then a phototherapeutical treatment of the nasal mucous membrane was started with a dose of 1 ⁇ MED.
- the patient interface 5 shown in FIG. 2B was brought into contact with the mucous membrane and this surface was irradiated during the treatment.
- the treatment was controlled visually under protection of ultraviolet protecting eyeglasses. This phototherapy was repeated three times per week. After the sixth treatment the symptoms of the patient decreased considerably, and after the eighth treatment the patient became free of symptoms. One month after stopping the therapy the patient was still free of symptoms.
- the ultraviolet part of the generated light was filtered out by choosing a non-ultraviolet-transmissive optical guidance system 4 .
- the treatment of the nasal mucous membrane was started with a dose of 20 J/cm 2 using patient interface 5 shown in FIG. 2B. Photodynamic therapy was then repeated twice weekly. Patient interface 5 was brought into contact with the nasal nucous membrane altogether in eight positions in each nostril. The treatment of the nostrils took approximately 10 minutes. The symptoms of the patient improved considerably after the second treatment and after two weeks the patient was completely free of symptoms. After stopping the therapy the symptoms of the patient did not return.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Radiation-Therapy Devices (AREA)
- Prostheses (AREA)
- Endoscopes (AREA)
- Photoreceptors In Electrophotography (AREA)
- Laser Surgery Devices (AREA)
- Container, Conveyance, Adherence, Positioning, Of Wafer (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Catching Or Destruction (AREA)
Abstract
A phototherapeutical apparatus is described, including a light source, generating high intensity visible light, in some embodiments in combination with ultraviolet light, an optical guidance system, and a patient interface. The patient interface can be insertable at least partially into a nasal cavity and is operable to apply the generated light to a tissue surface of the nasal cavity. Applying the apparatus includes providing the phototherapeutical apparatus, preparing for the application of the apparatus, inserting the patient interface into the nasal cavity, and applying the generated light by the patient interface to a tissue surface of the nasal cavity, wherein the tissue of the nasal cavity has an inflammatory or a hyperproliferative disease. The inflammatory diseases include rhinitis, sinusitis, and rhinosinusitis. A photodynamical therapy is also described, applying photosensitizing substances before the treatment with light. The phototherapeutical method is also effective for the prevention of inflammatory or hyperproliferative diseases.
Description
- The present application is a continuation-in-part of U.S. patent application by Lajos Kemény, Zsolt Bor, Gábor Szabó, Ferenc Ignácz, Béla Rácz, and Attila Dobozy, entitled: “Phototherapeutical Apparatus and Method for the Treatment and Prevention of Diseases of Body Cavities”, filed Apr. 9th 2003, which claims priority from Hungarian Patent Application P 0103279, filed on Aug. 10th 2001, and from PCT application PCT/HU01/00102, filed on Oct. 24th 2001.
- 1. Field of Invention
- The present invention relates to the treatment and prevention of inflammatory and hyperproliferative diseases of body cavities, more particularly to the treatment and prevention of diseases of the nasal cavity by phototherapeutical methods.
- 2. Description of Related Art
- The treatment and prevention of inflammatory diseases of the nasal mucous membrane and paranasal sinuses is an unsolved problem. These diseases include allergic rhinitis, commonly referred to as hay fever, vasomotor rhinitis, non-allergic eosinophilic rhinitis, chronic sinusitis, which is the inflammation of the paranasal sinuses, and nasal polyps.
- Rhinitis is an inflammatory disorder of the nasal mucous membrane, which is characterized by nasal itch, sneeze, nose running, nasal blockage, and rarely by loss of smelling. The inflammation of the nasal mucous membrane is frequently associated with the inflammation of the paranasal sinuses (rhinosinusitis, chronic sinusitis). As a consequence of the frequent and persistent inflammation of the mucous membrane hyperproliferative lesions, or so-called polyps develop on the mucous membrane.
- One characteristic disease is the allergic rhinitis, commonly referred to as hay fever. The allergic rhinitis is the most frequent allergic disease affecting 10-20% of the population. The number of patients with allergic rhinitis, especially in the well developed industrial countries increased very rapidly in the last few years. Because of the high number of patients the direct and indirect costs of this disease are great.
- Although hay fever is not a very severe disease, its unpleasant symptoms worsen the quality of life considerably. Hay fever is frequently associated with allergic conjunctivitis and sometimes with general symptoms. The symptoms last only for a few months in some patients (seasonal rhinitis), while in others they last the whole year (perennial rhinitis).
- The symptoms of the allergic diseases develop as follows. An allergen enters the body and induces the production of a specific IgE, which binds to specific receptors on the surface of mast cells. After subsequent exposure the allergen crosslinks the IgE receptors, resulting in mediator release from the mast cells. These mediators are responsible for the development of the symptoms in patient.
- As a result of this activation histamine and other preformed mediators are released from the mast cells. In the mast cells new inflammatory mediators are produced attracting further inflammatory cells into the mucous membrane (Howarth P H, Salagean M, Dokic D: Allergic rhinitis: not purely a histamine-related disease. Allergy 55: 7-16, 2000).
- At present there is no treatment for rhinitis, which would result in a complete elimination of the symptoms. The increased number of inflammatory cells in the nasal mucous membrane release mediators, which are responsible for the clinical symptoms. Often antihistamines are used locally or systemically for the blocking of the released mediators. Sodium cromoglycate is available for the inhibition of the release of mediators. Finally, corticosteroids are used locally or systemically for the blocking of the synthesis of new mediators. In special cases a desensitizing therapy might be used. The pathogenesis of the development of the clinical symptoms is already well known. However, the presently available drugs often do not eliminate the symptoms. Therefore, every new method for the treatment of this disease has a great medical significance.
- A further characteristic disease is vasomotor rhinitis. Vasomotor rhinitis is an inflammatory disorder of the nasal mucous membrane with unknown origin. The clinical symptoms are largely similar to that of allergic rhinitis: permanent nasal blockage, nasal itch, sneeze, nose running, and rarely loss of smelling. Mastocyte-activating mediators cause the symptoms. These are released from the nerve endings of the nasal mucous membrane upon irritation.
- A further characteristic disease is the nonallergic eosinophilic rhinitis. This disease is characterized by the high number of eosinophils in the nasal secretions and by the lack of an allergic origin. The disease is frequently associated with the development of nasal polyps, the hyperproliferative condition of the nasal mucous membrane. The clinical symptoms are the same as in allergic rhinitis.
- Additional diseases are rhinosinusitis and sinusitis. The inflammation of the paranasal sinuses is frequently associated with the inflammatory condition of the nasal mucous membrane (nasosinusitis). The isolated inflammation of the paranasal sinuses is also a frequent disease (sinusitis). This disease has often an allergic origin, although its exact cause remains unknown. There is no well-tested treatment, thus usually the same therapy is used as for rhinitis.
- Ultraviolet light has been used for more than twenty years for the treatment of allergic and auto-immune skin diseases. In various treatments and procedures ultravioletB light (280 nm-320 nm) and ultraviolet-A light (320 nm-400 nm) is used typically. The ultraviolet light inhibits the antigen-induced cellular immune response and is able to induce tolerance (Streilein J W, Bergstresser P R: Genetic basis of ultraviolet-B on contact hypersensitivity. Immunogenetics 27: 252-258, 1988).
- The ultraviolet light suppresses the immune reaction by inhibiting the antigen presentation and by inducing T-cell apoptosis. Irradiation of the skin with ultraviolet-B light or ultraviolet-A light on an area previously photosensitized by psoralen is known to inhibit the immunological processes in the skin. For the treatment of skin diseases there are a number of phototherapeutical devices available.
- These phototherapeutical devices include ultraviolet light sources. These light sources might be classified based on, for example, their operational principle, output energy or power, mode of operation (impulse or continuous), and whether they are emitting monochromatic or multiwavelength light.
- In early treatments broad band ultraviolet B (BB-UVB) light sources were used. In recent years more efficient narrow band ultraviolet B (NB-UVB) light sources became popular (Degitz K, Messer G, Plewig G, Röcken M: Schmalspektrum-UVB 311 nm versus Breitspektrum-UVB. Neue Entwicklungen in der Phototherapie. Hautarzt 49: 795-806, 1998).
- Our previous investigations of psoriatic patients indicated that the 308 nm xenon chloride excimer laser is more effective for phototherapeutical treatments than the NBUVB light sources (Bónis B, Kemény L, Dobozy A, Bor Zs, Szabó G, Ignácz F: 308 nm UVB excimer laser for psoriasis. Lancet 35: 1522, 1997; Kemény L, Bónis B, Dobozy A, Bor Z, Szabo G, Ignacz F: 308-nm excimer laser therapy for psoriasis. Arch Dermatol. 137: 95-96, 2001).
- Phototherapeutical treatments improved significantly with the appearance of ultraviolet light delivering optical systems. Such an ultraviolet light delivering phototherapeutical system with fiber optic is used in the Saalmann Cup instrument, in which the concentrated ultraviolet light is coupled into a fiber optic cable. Therefore, it is suitable for the treatment of smaller lesions of the skin or mucous membrane (Taube K M, Fiedler H: Hochkonzentrierte UV Bestrahlung kleiner Hautbezirke mit einem neuen Punktstrahler. Grundlagen und klinische Ergebnisse. Deutsche Dermatologe, 10: 1453, 1992).
- However, the Saalmann Cup can not be introduced into smaller body cavities because of its large contact area and because of the thickness of the used fiber optic cable. This device can be used in body cavities where the distal end of the fiber optic cable and the area to be treated can be visually controlled, such as the oral cavity. For this reason, this device is unsuitable for the treatment of body areas, which cannot be visually controlled, such as the nasal and paranasal mucous membrane, the gastrointestinal, and the urogenital mucous membrane.
- Although ultraviolet light has been used for the treatment of hyperproliferative and inflammatory skin diseases for many years, it has not been used for the treatment of common, immunologically mediated disorders of the nasal mucous membrane. In the U.S. Patent Application by Lajos Kemény, Zsolt Bor, Gábor Szabó, Ferenc Ignácz, Béla Rácz, and Attila Dobozy, entitled: “Phototherapeutical Apparatus and Method for the Treatment and Prevention of Diseases of Body Cavities”, filed Apr. 9th 2003, hereby incorporated by reference in its entirety, a phototherapeutical apparatus and method was described for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa and paranasal sinuses, such as allergic and non-allergic rhinitis, vasomotor fhinitis, allergic rhinosinusitis, and nasal polips. This method utilized ultraviolet light. Ultraviolet light was reported to be effective for the treatment of different forms of rhinitis, including hay fever. Also, ultraviolet light suppressed the development of nasal polips.
- Neuman and Finkelstein used narrow-band, low energy, red-light phototherapy for the treatment of the nasal mucous membrane and they found it effective for perennial allergic rhinitis but not for nasal polyposis (Neuman I., Finkelstein Y. Narrow-band red light phototherapy in perennial allergic rhinitis and nasal polyposis. Ann Allergy Asthma Immunol 78: 399-406, 1997). Neumann and Finkelstein irradiated the nasal mucosa using a 660 nm light emitting diode (LED) with a dose of 3 J/nostril day. They referred to their treatment as “a low-energy stimulation” as they used a 4 mW light emitting diode. As the total surface of the mucosa of one nostril is approximately 15 cm2, the nasal mucosa was illuminated with a total daily dose of approximately 0.2 J/cm2.
- In our patients cohort, we were not able to demonstrate the efficacy of this low energy, low intensity red light phototherapy for the treatment of hay fever. It should be noted, however, that high energy, high intensity visible light phototherapy has not previously been used for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa and paranasal sinuses such as allergic and non-allergic rhinitis, vasomotor rhinitis, allergic rhinosinusitis, and nasal polips.
- The photodynamic therapy (PDT) has been used for the last hundred years for the treatment of cancers. Many studies confirmed the efficacy of PDT for the treatment of different tumors in the last 30 years. In topical PDT, 5-aminolevulinate (ALA) is applied into the area to be treated. ALA is converted in situ into the active endogenous photosensitizer protoporphyrin IX, which sensitizes the hyperproliferative cells. Illumination of the lesions with high intensity visible light results in the production of singlet oxygen molecules, the presence of which causing the subsequent death of the sensitized cells.
- Recently a new, highly selective photosensitizer compound, methyl 5-aminolevulinate has also been introduced for use in topical PDT and many different studies confirmed its efficacy for the treatment of premalignant and malignant skin lesions (R. Szeimes et al.: Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective randomized study. Journal of the American Academy of Dermatology, vol. 47, p. 258, 2002) Although PDT has been used in many applications, it has not been used for the treatment of hay fever or nasal polips yet.
- There are a number of ultraviolet light delivery systems, which use lasers. For example, the light of the 308 nm xenon chloride excimer laser can be guided by fiber optic cable for the cleaning of root canals by ablation (Folwaczny M, Mehl A, Haffaer C, Hickel R: Substance removal on teeth with and without calculus using 308 nm XeCl excimer laser radiation. An in vitro investigation. J. Clin. Periodontol 26: 306-12, 1999). The 308 nm xenon chloride excimer laser is also suitable to treat artherosclerosis by treating the blood vessel walls (U.S. Pat. No. 4,686,979), or to enhance the cardiac oxygenization with transmyocardial laser revascularisation (U.S. Pat. No. 5,976,124), or inhibiting neovascularisation during angioplasty by destroying myocardial cells (U.S. Pat. No. 5,053,033).
- These systems share the common feature that the high-energy ultraviolet light at the end of the light delivering system is focused on small areas of only a few hundred microns in diameter. The photoablation produced by the intense ultraviolet light removes the undesired material. However, the intense ultraviolet light damages the tissues with its ablative effect.
- It is also known that larger skin lesions can be treated by using a number of small fiber optic cables (U.S. Pat. No. 6,071,302; WO9607451, Asawanonda P, Anderson R R, Chang Y, Taylor C R: 308-nm excimer laser for the treatment of psoriasis: a doseresponse study. Arch Dermatol 136: 619-24, 2000).
- Phototherapeutical systems attached to endoscopes are also used for the photodynamic treatment of tumors, such as bladder carcinoma or bronchial cancer. However, these instruments have special distal ends for tumor treatment (U.S. Pat. Nos. 4,313,431; 4,612,938; 4,676,231; 4,998,930; 5,146,917).
- At present, the phototherapeutical systems delivering light consist of a hand piece specifically shaped to a specific treatment. As such, they are either unsuitable or inconvenient for the treatment of small body cavities such as the nasal cavity with visual control.
- Briefly and generally, embodiments of a phototherapeutical apparatus are described, the apparatus including: a light source, operable to generate high intensity visible light, an optical guidance system, operable to receive and guide the high intensity visible light of the light source, and a patient interface, operable to receive the guided light from the optical guidance system, wherein the patient interface is operable to apply the guided light to a tissue surface of a nasal cavity. In some embodiments the patient interface is insertable at least partially into a nasal cavity.
- Further, embodiments of a method of treating diseases is described. The method includes providing a phototherapeutical apparatus, which includes a light source, operable to generate high intensity visible light, an optical guidance system, coupled to the light source, and a patient interface, coupled to the optical guidance system. The method further includes preparing for the application of the phototherapeutical apparatus, inserting at least partially the patient interface into a nasal cavity, generating high intensity visible light with the light source, coupling the high intensity visible light into the patient interface through the optical guidance system, and applying the high intensity visible light by the patient interface to a tissue surface of the nasal cavity, wherein the tissue of the nasal cavity has an inflammatory disease or a hyperproliferative disease.
- Examples of inflammatory diseases include the inflammatory diseases of the nasal cavity. Research showed that single or repeated irradiation of the nasal mucous membrane and paranasal sinuses with high intensity visible light, or with a combination of visible light with ultraviolet light (of the UVB or UVA type, or both) suppress the clinical symptoms of rhinitis, sinusitis, and rhinosinusitis, and result the regression of nasal polyps.
- In some embodiments of the phototherapeutical method photodynamic therapeutical methods are included, where a photosensitizing substance, such as deltaaminolevolunic acid is applied to the tissue surface before irradiation with light.
- The phototherapeutical apparatus is also effective for the prevention of inflammatory diseases or hyperproliferative diseases. In these embodiments of the method phototherapy is applied before the appearance of clinical symptoms of the disease.
- For a more complete understanding of the present invention and for further features and advantages, reference is now made to the following description taken in conjunction with the accompanying drawings.
- FIG. 1 illustrates an embodiment of the phototherapeutical apparatus according to the invention.
- FIGS.2A-B illustrate exemplary implementations of the light source and the phototherapeutical apparatus according to an embodiment of the invention.
- FIG. 3 illustrates an exemplary implementation of the optical coupling unit according to an embodiment of the invention.
- FIG. 4 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 5 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 6 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 7 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 8 illustrates an exemplary implementation of the patient interface according to an embodiment of the invention.
- FIG. 9 illustrates a phototherapeutical apparatus including a flexible endoscope, according to an embodiment of the invention.
- FIG. 10 illustrates steps of the phototherapeutical method, according to an embodiment of the invention.
- FIG. 11 illustrates the decrease of clinical symptoms due to treatment with an embodiment of the phototherapeutical method, according to an embodiment of the invention.
- FIG. 12 illustrates the decrease of clinical symptoms due to treatment with an embodiment of the photodynamic therapeutical method, according to an embodiment of the invention.
- Embodiments of the present invention and their advantages are best understood by referring to FIGS.1-12 of the drawings. Like numerals are used for like and corresponding parts of the various drawings.
- The Phototherapeutical Apparatus
- The phototherapeutical apparatus, according to embodiments of the present invention is suited for the treatment and prevention of common inflammatory diseases of the body. In some applications the phototherapeutical apparatus is used for the treatment and prevention of the diseases of a nasal mucous membrane and paranasal sinuses such as allergic rhinitis (hay fever), vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis (inflammation in the paranasal sinuses), or nasal polyps. Some embodiments of the phototherapeutical apparatus utilize visible light. Some embodiments utilize a combination of visible light and ultraviolet light. Some embodiments utilize high intensity light.
- FIG. 1 illustrates a
phototherapeutical apparatus 100, according to an embodiment of the invention.Phototherapeutical apparatus 100 includes alight source 1.Light source 1 is operable to generate alight beam 2 of visible light, ultraviolet light, or a combination of visible and ultraviolet light.Light source 1 is operable to generate high intensity light.Light beam 2 enters into anoptical coupling unit 3, wherelight beam 2 is focused. The focused light beam is coupled byoptical coupling unit 3 into anoptical guidance system 4.Optical guidance system 4 guides the focused light beam into apatient interface 5.Patient interface 5 is insertable at least partially into a body cavity, where it applies the light beam to a tissue surface of a body cavity. FIG. 1 illustrates an embodiment, where the body cavity is the nasal cavity and the patient interface is inserted through anostril 6. - In some embodiments
light source 1 generates a continuous light beam, in others a slowly oscillating light beam. For example, in some embodiments the frequency of oscillations can be below about 100 Hertz. In various embodiments the continuous light beam and slowly oscillating light beam will be jointly referred to as quasi-continuous light beam. -
Light source 1 can be, for example, a monochromatic light source or a multiwavelength light source. - A variety of monochromatic light sources, such as lasers, can be used as
light source 1. Examples include any type of diode lasers or other lasers emitting high intensity light in the visible spectrum. Also, a variety of multiwavelength light sources can be used aslight source 1. Examples include electric discharge lamps, arc lamps filled with xenon, mercury vapour, xenon and mercury vapour, fluorescent lamps, and light emitting diodes (LEDs). - In some embodiments substantially all of the light, generated by
light source 1, is visible light, i.e. it has a wavelength in the visible spectrum, between about 400 nm and about 700 nm. In some embodiments the wavelength is in the high energy portion of the visible spectrum, between about 400 nm and about 600 nm. - In embodiments the generated visible light has a dose up to about 100 J/cm2 on the targeted tissue. In some embodiments light beams with a dose between about 10 J/cm2 and about 100 J/cm2 will be referred to as high intensity light. The range of the dose of the light may depend on the specific patient. For some patients a light with a dose of, for example 4 J/cm2 or 7 J/cm2 may be already high intensity.
- In some embodiments
light source 1 generates a certain amount of ultraviolet light simultaneously with the visible light. The ultraviolet light can have a wavelength in the ultraviolet-B (280 nm-320 nm) and ultraviolet-A (320 nm-400 nm) part of the spectrum. - FIG. 2A illustrates an example of
light source 1, operable to generate visible light, ultraviolet light, or a combination of visible and ultraviolet light, according to embodiments of the invention. An electricpower supply unit 7 is connected toelectrodes 11 bywires 8.Electrodes 11 enter the internal space ofquartz bulb 12, which is filled with gas. The electric power, provided byelectric power supply 7 causes an electric discharge in the gas. During this discharge light is generated. The wavelength of the light depends, among others, on the chemical composition of the gas. With a suitable choice of the chemical composition of the gas the generated light will have a wavelength in the visible spectrum or in the ultraviolet spectrum. In some embodiments the gas or gas mixture inquartz bulb 12 can include xenon, argon, and mercury vapor, and any other gas that emit light substantially in the visible spectrum, possibly with a portion emitted in the ultraviolet spectrum. Part of the light, generated in the discharge space, propagates directly towards focusinglens 15. Other portions of the generated light propagate in other directions. Part of these portions are reflected byconcave mirror 9 toward focusinglens 15. Focusinglens 15 focuses all incoming light efficiently into alight beam 2. The focusedlight beam 2 leaveshousing 10 through anoutput opening 14 and reaches anoptical filter 13. In some embodimentsoptical filter 13 transmits visible light, ultraviolet A, or ultraviolet B, or any combination of light. Fromoptical filter 13 the filtered and focusedlight beam 2 is coupled into anoptical guidance system 4. - The volume of the discharge space in
quartz bulb 12 varies in the range of about 1 mm3 to about 0.1 mm3. In some embodiments the discharge space is positioned approximately in the focus ofconcave mirror 9, soconcave mirror 9 can efficiently focus the emitted light onto focusinglens 15. - FIG. 2B illustrates a
phototherapeutical apparatus 100, according to a related embodiment of the invention.Power supply 7 provides adjustable power forapparatus 100.Power supply 7 may include a medical grade isolation transformer. The isolation transformer also provides protection from electrical shock.Quartz bulb 12 is operable to generate light with a wavelength between about 280 nm and about 700 nm. In someembodiments quartz bulb 12 is operable to generate light with a wavelength between about 280 nm and about 600 nm. An embodiment ofquartz bulb 12 is an electric microdischarge lamp. In embodiments the length of discharge space, or “arc”, is between about 1 mm and about 10 mm. Because of the smallness of the discharge volume it is easy to collect the generated light and to couple it intooptical guidance system 4. As an example, an electric micro-discharge lamp with a power of about 35 watts may output between about 0.1 watts to about 2 watts atpatient interface 5. - Previous examples of arc lamps include mercury and mercury xenon lamps, described, for example, by Hartmann et al. in Patent Application WO 02/13905. In these lamps the discharge space is bigger. Accordingly, these lamps need a power of 500 to 1500 watts to
output 2 to 4 watts atpatient interface 5. In contrast, embodiments of the present invention utilize micro-discharge lamps. These substantially smaller discharge lamps can operate with a power of about 35 watts. Micro-discharge lamps also produce much less heat. Therefore, in some embodiments no ventilation is necessary to cool the micro-discharge lamp during usage. Because of the small lamp size some embodiments of the phototherapeutical device are portable. For example, embodiments of the device can be powered through the cigar lighter of an automobile. - The generated
light beam 2 is coupled byoptical coupling unit 3 intooptical guidance system 4.Optical coupling unit 3 includesoptical filter 13 andbeam shutter 110.Optical filter 13 is operable to select a range of wavelengths from the overall wavelength range oflight beam 2. Commercially availableoptical filters 13 include SCHOTT GG 400 (manufactured by Schott A. G., Germany), which is operable to filter out the ultraviolet portion oflight beam 2 with wavelengths below about 400 nm. Optical filter SCHOTT WG 320 (Schott A. G., Germany) is operable to filter out the ultraviolet-B portion of the spectrum, below about 320 nm.Beam shutter 10 is controlled and monitored by acontrol panel 106.Control panel 106 may include an electronic timing unit, which is operable to log the operational ON time ofpower supply 7. The intensity oflight beam 2 is adjustable by controlling the current output ofpower supply 7.Phototherapeutical apparatus 100 can be pre-programmed throughcontrol panel 106. Pre-programming may include selecting a treatment irradiant dosage by setting the timing unit and adjusting the intensity oflight beam 2 by setting the current ofpower supply 7. Some embodiments may include afootswitch 104.Footswitch 104 can be used to convenient application ofapparatus 100. For example, footswitch can be used to start a pre-programmed application ofapparatus 100. -
Light beam 2 is coupled byoptical coupling unit 3 intooptical guidance system 4.Optical guidance system 4 might provide additional optical filtering. Embodiments ofoptical guidance system 4 include an optical cable with a core diameter between about 1 mm and about 10 mm.Optical guidance system 4 coupleslight beam 2 intopatient interface 5.Patient interface 5 may be inserted into the nasal cavity of a patient. FIG. 2B shows a hollow plastic tip as apatient interface 5. Several additional embodiments ofpatient interface 5 will be described below.Patient interface 5 might also provide additional optical filtering.Patient interface 5 may include a tip which transmits visible light but does not transmit ultraviolet light, or a tip which transmits both visible and ultraviolet light. - FIG. 3 illustrates an embodiment of
optical coupling 3.Light beam 2 enteringoptical coupling unit 3 is directed by adichroic mirror 16 intooptical guidance system 4 through alens system 17.Dichroic mirror 16 simultaneously performs a spectral filtering oflight beam 2. - In some embodiments
optical guidance system 4 is also applicable to guide back reflected light, reflected from the site of application. The light emerging from the site of the application passesdichroic mirror 16 and can be detected through an observingoptical device 19 to assist the application of the phototerapeutical device. -
Optical guidance system 4 can be, for example, an optical cable or arm suitable to guide light. The optical cable or arm can be formed of any one of a large number of known suitable materials, among others quartz glass or capillary tubes filled with a liquid capable of guiding light, wherein the internal surface of the capillary tubes are covered with ultraviolet reflecting material. The diameter of the optical cable can be between about 1 micron and about 10 mm. In some embodimentsoptical guidance system 4 also performs a spectral filtering oflight beam 2. - FIG. 4 illustrates an embodiment of
patient interface 5, suitable for the treatment of the nasal mucous membrane and paranasal sinuses.Patient interface 5 is suited to be positioned at least partially in the nostril or nasal cavity of a patient and guidelight beam 2 onto the tissue surface to be treated. Many variations ofpatient interface 5 can be constructed and are meant to be within the scope of the invention. - In the embodiment of FIG. 4
optical guidance system 4 is attached tohandgrip 20. The guided light enters fromoptical guidance system 4 throughhandgrip 20 intooptical tube 22 and propagates into atapered end piece 24. Ahead 25 ofpatient interface 5 is coupled tooptical tube 22 by afastener 23. Ascanning light source 27 is included to illuminate the area of the tissue surface to be treated. Scanninglight source 27 is built intohandgrip 20 and can be powered by either an internal or an external power supply unit.Mirror 28 reflects the scanning light ofscanning light source 27 onto the tissue surface to be treated.Light beam 2 and the scanning light propagate throughoutput opening 26 onto the tissue surface to be treated. The end ofpatient interface 5, wherelight beam 2 leavespatient interface 5 is sometimes referred to as the distal end. In the present embodiment the distal end is whereoutput opening 26 is positioned. A magnifyingglass 21 mounted ontopatient interface 5 provides visual control of the application of the light ofphototherapeutical apparatus 100. - FIG. 5 shows another embodiment of
patient interface 5, wherein thelight beam 2 enters fromoptical guidance system 4 through alens 29 ofhandgrip 20.Light beam 2 is then reflected ondichroic mirror 16, which is mounted insideoptical tube 22, and leavespatient interface 5 throughoutput opening 26 ofhead 25. In this embodiment scanninglight source 27 is mounted insidehandgrip 20. The scanning light passes throughdichroic mirror 16 and is reflected by concave holedmirror 30 to illuminate the tissue surface to be treated. - In various embodiments external scanning light sources are applied to illuminate the tissue area to be treated.
- FIG. 6 illustrates another embodiment of
patient interface 5. In this embodimentoptical guidance system 4 is coupled into a pen-shapedhandgrip 31.Light beam 2 enters pen-shapedhand grip 31 and is reflected by flatsurface treating head 32. Flat surface treating head can include, among others, a quartz prism or a flat mirror. Flatsurface treating head 32 is coupled to pen-shapedhandle 31 with afastener 23. - FIG. 7 illustrates another embodiment of
patient interface 5, which is suitable for the circular treatment of a body cavity, for example, the nasal cavity. In this embodimentoptical guidance system 4 guideslight beam 2 into pen-shapedgrip 31, where it is reflected bycircular reflector 33 in a circular manner.Circular reflector 33 can be, for example, a conical or a spherical reflecting surface.Circular applicator head 34, housingcircular reflector 33, is coupled to pen-shapedhandle 31 withfastener 23. Body cavities, such as the nasal cavity can be treated with this embodiment in a circular manner. - FIG. 8 illustrates another embodiment of
patient interface 5, which is suited for a spot treatment of tissue surfaces, such as the nasal mucous membrane.Optical guidance system 4 guideslight beam 2 into pen-shapedhandle 31, where it is guided onto a spot on the tissue to be treated byspot applicator 36.Spot applicator 36 can be, for example, a plano-parallel disk or alens 36 made of quartz or plastic transparent to light.Spot applicator 36 is housed byspot applicator head 35, which is fastened onto pen-shapedhandle 31 by afastener 23. - FIG. 9 illustrates another embodiment of
patient interface 5, which is suited for a spot treatment of tissue surfaces, such as the nasal mucous membrane.Light beam 2 generated bylight source 1 is focused and coupled byoptical coupling unit 3 intooptical guidance system 4. Optical guidance system is integrated intoflexible endoscope 37.Flexible endoscope 37 is capped withpatient interface 5.Patient interface 5 includes aspot applicator 36.Spot applicator 36 can be, for example, a plano-parallel disk or alens 36 made of quartz or plastic transparent to light. In someembodiments spot applicator 36 can have a sloped distal end. - In order to illuminate the tissue surface to be treated, a scanning light is provided by scanning
light source 27. The generated scanning light is guided throughlens 41 into scanningoptical cable 42. Scanningoptical cable 42 can be also integrated intoflexible endoscope 37. The scanning light illuminates the tissue surface to be treated throughpatient interface 5. - Light reflected from the illuminated tissue surface is conducted back from the illuminated tissue surface via image processing
optical cable 38, which can be integrated intoflexible endoscope 37 as well. Image processingoptical cable 38 is coupled intoimage processing unit 39 to facilitate visual control of the application of the phototerapeutical apparatus. - In some embodiments
optical guidance system 4 can be rotated withinflexible endoscope 37 by positioningunit 40, so that the direction oflight beam 2 emitted throughpatient interface 5 can be modified. In other embodimentsflexible endoscope 37 itself can be rotated by positioningunit 40. These embodiments are useful for the treatment of various body cavities, for example, a larynx, a digestive canal, and urogenital organs. - Some embodiments for the circular and the spot treatment of tissue surfaces may include a Panoramic Annular Lens (PAL) optical system. A PAL system, transparent to the light can be included into
circular applicator head 34 andspot applicator head 35. Including a PAL optical system can be helpful for simultaneous treatment of tissue surfaces and optical image processing. - Phototherapeutical Method
- According to embodiments of the invention, a
phototherapeutical method 200 is described for the treatment and prevention of inflammatory and hyperproliferative diseases of body cavities, more particularly for the treatment and prevention of common inflammatory diseases of the nasal mucous membrane and paranasal sinuses, including allergic rhinitis (hay fever), vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis (inflammation in the paranasal sinuses), and for the treatment and prevention of hyperproliferative diseases, including nasal polyps (a frequent benign hyperproliferative lesion in chronic inflammatory conditions of the nasal mucous membrane). -
Phototherapeutical method 200 is based on the inventor's research results, which showed that the application of visible light, or a combination of visible and ultraviolet light to tissue surfaces in the nasal cavity decreases the number and the activity of inflammatory cells (mast cells, eosinophils, and lymphocytes) responsible for the mediator release and synthesis in the mucous membrane, and thereby it reduces the clinical symptoms of inflammatory, hyperproliferative, and allergic diseases. - FIG. 10 illustrates steps of
phototherapeutical method 200. Instep 204phototherapeutical apparatus 100 is provided, whereinphototherapeutical apparatus 100 includes:light source 1,optical guidance system 4, coupled tolight source 1, andpatient interface 5, coupled tooptical guidance system 4.Phototherapeutical method 200 can be practiced with any embodiment ofphototherapeutical apparatus 100, described earlier. - In some embodiments,
light source 1 is operable to generate high intensity visible light. High intensity light includes light with a dose between about 10 J/cm2 and about 100 J/cm2. In some embodimentslight source 1 generates visible light in the high energy portion of the spectrum, with wavelength between about 400 nm and about 600 nm. When visible light is used alone, without combination with UV light, high intensity light achieves significant immunosuppression in the nasal mucosa. The present method of using high intensity visible light differs from other methods using low-intensity light emitting diodes. Some low intensity methods apply red light in a dose of about 0.2 J/cm2, therefore the present method applies light in orders of magnitude higher doses. - In
step 204 some embodiments ofphotoherapeutical apparatus 100 include essentially monochromatic light sources, other embodiments include multiwavelength light sources. Embodiments with monochromatic light sources include, for example, any type of diode lasers, or any other lasers, which emit light in the visible spectrum. - Multiple wavelengths embodiments include, for example, discharge lamps and arc lamps. Each of these lamps can be filled, for example, with xenon, mercury vapour, and a mixture of xenon and mercury vapour. Other embodiments include fluorescent lamps, light emitting diodes (LEDs), and dye lasers.
- In step206 a preparation for the treatment by
phototheraputical method 200 is performed. The preparation can include—in case of a combined visible and ultraviolet light treatment—determining a light threshold of the particular patient on a part of the patient's skin, which was not recently exposed to sunlight. One measure of a light threshold is the Minimal Erythema Dose (MED). The MED is the smallest dose of combined light, which causes erythema on the patient's previously unexposed skin after 24 hours. The MED is then used to determine the value of the first dose, applied to the area to be treated. The preparation can further include treatment of the nasal mucosa with nasal decongestants to decrease the odema of the nasal mucosa in order to be able to illuminate larger mucosa surfaces. - The preparation can further include selecting a
suitable patient interface 5 for practicingphototherapeutical method 200. This choice depends, for example, on the location of the area of the tissue surface to be treated and the anatomy of the body cavity of the patient. - In
step 212 high intensityvisible light beam 2 is generated bylight source 1. - In
step 216 the generated high intensityvisible light beam 2 is coupled intopatient interface 5 throughoptical guidance system 4. - In
step 220 the generated high intensity visible light is applied bypatient interface 5 to a tissue surface of a nasal cavity. In some embodiments of the method,step 220 includes insertingpatient interface 5 at least partially into the nasal cavity.Patient interface 5 is inserted at the distal end. - In some embodiments of
step 220, where the tissue surface is the nasal mucous membrane, a high intensity visible light was applied throughpatient interface 5 with a dose between about 10 J/cm2 and about 100 J/cm2. - The treatment with such high intensity visible light can be repeated one or more times per week. The repeated application of such high intensity visible light can be performed with the same dose or with increasing doses, depending on the patient's tolerance and on the improvements of the clinical symptoms.
- In some embodiments of
step 220, where the tissue surface is the nasal mucous membrane, the high intensity visible light was applied in a dose between about 10 J/cm2 and about 100 J/cm2, in combination with ultraviolet-A light (320 nm-400 nm) in a dose between about 1 J/cm2 and about 10 J/cm2, or ultraviolet-B light (295-320 nm) in a dose between about 0.01 J/cm2 and about 1.0 J/cm2, or both. In some embodiments the high intensity visible light was the high energy portion of the visible spectrum, with wavelength between about 400 nm and about 600 nm. - Research indicated that the clinical symptoms of the treated nasal mucous membrane improved considerably with the treatment. These symptoms include nasal blockage, nasal itch, nose running, sneezing, and itching of the palate in patients with allergic rhinitis.
- In several cases the symptoms improved when high energy visible light was applied, or visible light in combination with ultraviolet light.
- In some embodiments of the method, the previously determined MED value is used to determine the first dose, applied to the tissue surface to be treated.
- FIG. 11 illustrates the improvement of hay fever symptoms of the nasal mucous membrane as a result of being treated by
phototherapeutic method 200. The illustrated embodiment ofmethod 200 used visible light (400 nm-700 nm) in high doses. The severity scores of hay fever (0=no symptoms, 3=very severe symptoms) are shown before the treatment and after a 3-week treatment. The treatment included using the same dose four times per week. As shown, the clinical symptoms and complaints of the patients decreased significantly after the treatment. - Similar improvements were observed in the clinical symptoms of vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis, and in the sizes of nasal polyps after treatment with
phototherapeutical method 200. The clinical symptoms decreased considerably after the treatment. - In some embodiments the preparation of
step 206 includes increasing the efficacy ofphototherapeutical method 200 by administering photosensitizing substances before the phototherapy with visible light. Sometimes this method is referred to as photodynamic therapy (PDT). Example for photosensitizing substances include porphirin precursors such as 5-aminolevulinate, or metabolites of porphirin precursors, or other synthetic porphirin precursors such as methyl 5-aminolevulinate. These materials can be used in concentrations between about 1% and about 20%. - In some embodiments the preparation of
step 206 includes increasing the efficacy ofphototherapeutical method 200 by administering a combined high intensity visible light with ultraviolet light. When a visible light is applied in combination with ultraviolet light, the minimal erythema dosis (MED) can be measured on a part of the patient's skin, which was not exposed to sunlight before starting the therapy. The MED is the smallest ultraviolet dose, which induces erythema on a previously unexposed skin after 24 hours. - In
step 220 the high intensity visible light in combination with ultraviolet light is applied to the nasal mucous membrane. The application can be started with a dose about 1.0×MED to about 2.0×MED, depending on the severity of the symptoms of the patient. During repeated applications in some embodiments the dose remains approximately constant. In other embodiments the dose is increased depending on the patient's tolerance. Step 220 can be repeated once or several times per week. Research showed that phototherapy inhibits rapidly and effectively the clinical symptoms of hay fever, including nasal blockage, nasal itch, nose running, sneezing and itching of the palate. - FIG. 12 illustrates the improvement of hay fever symptoms of the nasal mucous membrane as a result of being treated by the combined visible/ultraviolet
phototherapeutic method 200. In this embodiment of themethod light source 1 is an electric discharge lamp, emitting more than 98% of its power with wavelength between about 320 nm and about 650 nm and approximately 2% of its power with wavelength between about 295 nm and 320 nm. The severity scores of hay fever (0=no symptoms, 3=very severe symptoms) are shown before the treatment and after a 3-week treatment. The treatment was applied twice per week with essentially constant doses. All the clinical symptoms and complaints of the patients decreased substantially after the phototherapy. - Similar improvements are observed in the clinical symptoms of vasomotor rhinitis, nonallergic eosinophilic rhinitis, chronic sinusitis, and the sizes of nasal polyps considerably decreased after such a combined high intensity visible light/ultraviolet phototherapy.
-
Phototherapeutical method 200 is also suitable for the prevention of inflammatory and hyperproliferative diseases of nasal cavities. For example, in the case of seasonal allergicrhinitis phototherapeutical method 200 can be started before the appearance of the clinical symptoms. - Similarly,
phototherapeutical method 200 with photochemotherapy is also suitable for the prevention of the clinical symptoms of patients with seasonal allergic rhinitis. The treatment can be started before the appearance of the symptoms. The treatment can be administered once or several times per week depending on the tolerance of the patient. - Finally it is noted that the application of
phototherapeutical method 200 is significantly cheaper than presently practiced drug based treatments. - Potential Side Effects
- When visible light is used in combination with ultraviolet light for the treatment, the ultraviolet light might facilitate the appearance of viral and bacterial infections on the treated areas because of its immunosuppressive effect. This effect is similar to the effect of topical corticosteroides. However, the likelihood for these infections is lower than that of the presently used local immuno-suppressive preparations, because light also has a direct microbicidal effect (Folwaczny M, Liesenhoff T, Lehn N, Horch H H: Bactericidal action of 308 nm excimer-laser radiation: an in vitro investigation. J Endodontics, 24: 781-785, 1998). Furthermore, light also increases the direct microbicidal activity of epithelial cells (Csató M, Kenderessy SzA, Dobozy A: Enhancement of Candida albicans killing activity of separated human epidermal cells by ultraviolet radiation. Br J Dermatol 116: 469-475, 1987).
- Practicing
phototherapeutical method 200 withphototherapeutical apparatus 100 is further illustrated through the following examples. - Treatment of Hay Fever with High Intensity Visible Light
- The severe symptoms of a patient with ragweed-induced hay fever did not respond to the antihistamine and topical corticosteroid therapy. At examination the patient complained of severe nasal blockage, nasal itching, nose running, frequent snecezing and itching of the nasal palate. Phototherapy of the nasal mucous membrane was started. For this purpose high intensity visible light of
light source 1 was generated by an electric discharge lamp and the generatedlight beam 2 was coupled by optical focusing usingconcave mirror 9 intooptical guidance system 4.Optical guidance system 4 was an optical cable with a diameter of 5.0 mm. The optical cable was connected topatient interface 5 shown in FIG. 2B. The treatment of the nasal mucous membrane of the patient was started with a dose of 50 J/cm2. The complete time of a treatment was 15 minutes and the treatment did not cause any complaint by the patient. The treatment was then repeated three times per week using the same phototherapeutical apparatus, but the irradiation dose was increased by 20% each occasion. After the fourth treatment the symptoms and complaints of the patient decreased to a large extent and in the third week after the nine treatment the patient was completely free of symptoms. The treatment was stopped and no recurrence was observed. The patient found this type of therapy to be more efficacious as compared to the previously used therapies. - Treatment of Hay Fever with a Combination of High Intensity Visible Light and Ultraviolet Light
- A patient with severe hay fever due to ragweed allergy did not impove under conventional therapy with antihistamines and corticosteroids. Therefore, an embodiment of
phototherapeutical method 200 was administered. A speciallight source 1 was used to generate ultraviolet and high intensity visible light. The intensity of the light at the output end ofpatient interface 5 was 700 mW/cm2. The UVB (300-320 nm wavelengths) content oflight beam 2 was 1%, the UVA (320 nm-400 nm) content was 13%, and the remaining 84% was in the visible (400-650 nm) portion of the spectrum. The minimal erythema dosage (MED) was first determined on the forearm of the patient not exposed to sunlight earlier, then a phototherapeutical treatment of the nasal mucous membrane was started with a dose of 1×MED. Thepatient interface 5 shown in FIG. 2B was brought into contact with the mucous membrane and this surface was irradiated during the treatment. The treatment was controlled visually under protection of ultraviolet protecting eyeglasses. This phototherapy was repeated three times per week. After the sixth treatment the symptoms of the patient decreased considerably, and after the eighth treatment the patient became free of symptoms. One month after stopping the therapy the patient was still free of symptoms. - Treatment of Hay Fever with Photodynamic Therapy
- The clinical symptoms of a patient suffering from ragweed-induced hay fever did not respond satisfactorily after using antihistamines and topical corticosteroid nasal drops. At examination the symptoms (nasal blockage, nasal itching, nose running, frequent sneezing, and itching of the nasal palate) of the patient were severe, therefore an embodiment of a photodynamic therapy was performed. The nasal mucosa was treated with 20% 5-deltaaminolevalunic acid (DALA)
lotion 3 hours before phototherapy. For the phototherapy,light source 1 of the type shown in FIG. 2B was used, generating light with wavelengths between 300 nm and 700 nm. The ultraviolet part of the generated light was filtered out by choosing a non-ultraviolet-transmissiveoptical guidance system 4. The treatment of the nasal mucous membrane was started with a dose of 20 J/cm2 usingpatient interface 5 shown in FIG. 2B. Photodynamic therapy was then repeated twice weekly.Patient interface 5 was brought into contact with the nasal nucous membrane altogether in eight positions in each nostril. The treatment of the nostrils took approximately 10 minutes. The symptoms of the patient improved considerably after the second treatment and after two weeks the patient was completely free of symptoms. After stopping the therapy the symptoms of the patient did not return. - Treatment of Nasal Polips with Photodynamic Therapy
- A patient had a large polyp in the right nostril, that has been operated already several times. The patient had also severe perennial rhinosinusitis, possibly inducing the recurrence. A 20% DALA solution was applied to the nasal polip. Three hours thereafter visible light phototherapy using
light source 1 was used to generate and deliver high intensity visible light to the affected area.Light source 1 of the type shown in FIG. 2B was used, generating light with wavelengths between 300 and 700 nm. The ultraviolet part of the emitted spectrum was filtered out by choosing a non-UV-transmissiveoptical guidance system 4. The treatment of the nasal mucous membrane was started with a dose of 60 J/cm2 usingpatient interface 5 shown in FIG. 2B. Five days after one single treatment the nasal polyp disappeared without any scar formation. The photodynamic therapy was then repeated once weekly for 8 weeks. After stopping the therapy the nasal polip did not return. All complaints of the patient disappeared as well. - Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions, and alterations can be made therein without departing from the spirit and scope of the invention as defined by the appended claims. That is, the discussion included in this application is intended to serve as a basic description. It should be understood that the specific discussion may not explicitly describe all embodiments possible; many alternatives are implicit. It also may not fully explain the generic nature of the invention and may not explicitly show how each feature or element can actually be representative of a broader function or of a great variety of alternative or equivalent elements. Again, these are implicitly included in this disclosure. Where the invention is described in device-oriented terminology, each element of the device implicitly performs a function. Neither the description nor the terminology is intended to limit the scope of the claims.
Claims (29)
1. A phototherapeutical apparatus, comprising:
a light source, operable to generate high intensity, visible light;
an optical guidance system, operable to receive and guide the light of the light source; and
a patient interface, operable
to receive the guided light from the optical guidance system; and
to apply the guided light to a tissue surface of a nasal cavity.
2. The phototherapeutical apparatus of claim 1 , wherein
the patient interface is insertable at least partially into the nasal cavity.
3. The phototherapeutical apparatus of claim 1 , wherein the light source is capable of generating a combination of visible and ultraviolet light with wavelengths in the range of about 280 nm to about 700 nm.
4. The phototherapeutical apparatus of claim 1 , wherein the light source is capable of generating a combination of visible and ultraviolet light with wavelengths in the range of about 280 nm to about 600 nm.
5. The phototherapeutical apparatus of claim 1 , wherein
high intensity light comprises light with a dose between about 10 J/cm2 and about 100 J/cm2.
6. The phototherapeutical apparatus of claim 1 , wherein the light source is one of an essentially monochromatic light source and a multiwavelength light source.
7. The phototherapeutical apparatus of claim 6 , wherein the light source is one of a laser, a fluorescent lamp, a light emitting diode, a dye laser, an arc lamp, and an electric discharge lamp, the electric discharge lamp comprising at least one of xenon, argon, and mercury vapor.
8. The phototherapeutical apparatus of claim 6 , wherein the multiwavelength light source comprises:
a quartz bulb, capable of generating an arc with a length between about 1 mm and about 10 mm.
9. The phototherapeutical apparatus of claim 1 , wherein the phototherapeutical apparatus comprises:
a concave mirror, reflecting a portion of the generated light;
a focusing lens, operable to focus a portion of the generated light and a portion of the reflected light;
an optical filter, operable to receive and filter the focused light; and
a beam shutter, operable to control the generated light.
10. The phototherapeutical apparatus of claim 1 , wherein the optical guidance system comprises at least one of:
an optical cable, having a diameter between about 1 micron and about 10 mm and comprising quartz glass fiber; and
an optical arm, comprising at least one capillary tube, wherein the tube contains an light conducting fluid, and wherein the internal surfaces of the tube are at least partially covered with an light reflecting coating.
11. The phototherapeutical apparatus of claim 1 wherein the phototherapeutical apparatus is applicable for at least one of the treatment and the prevention of inflammatory and hyperproliferative diseases, comprising:
allergic rhinitis, rhinusitis, vasomotor rhinitis, non-allergic eosinophilic rhinitis, chronic sinusitis, and diseases of mucous membranes of the gastrointestinal and urogenital systems.
12. A method of treating diseases, the method comprising:
providing a phototherapeutical apparatus, comprising:
a light source, capable of generating high intensity visible light;
an optical guidance system, coupled to the light source; and
a patient interface, coupled to the optical guidance system;
preparing for the application of the phototherapeutical apparatus;
generating high intensity visible light with the light source;
coupling the high intensity visible light into the patient interface through the optical guidance system; and
applying the high intensity visible light by the patient interface to a tissue surface of a nasal cavity, wherein
the tissue of the nasal cavity has at least one of an inflammatory disease and a hyper-proliferative disease.
13. The method of claim 12 , wherein the applying the light by the patient interface comprises:
inserting the patient interface at least partially into the nasal cavity.
14. The method of claim 12 , wherein the light source is capable of generating a combination of visible light and ultraviolet light, with wavelengths in the range of about 280 nm to about 700 nm.
15. The method of claim 12 ,.wherein the light source is capable of generating a combination of visible light and ultraviolet light, with wavelengths in the range of about 280 nm to about 600 nm.
16. The method of claim 12 , wherein the applying the light comprises
applying the high intensity visible light with a dose between about 10 J/cm2 and about 100 J/cm2.
17. The method of claim 12 , wherein the light source is one of an essentially monochromatic light source and a multiwavelength light source.
18. The method of claim 12 , wherein the light source is one of a laser, a fluorescent lamp, a light emitting diode, a dye laser, an arc lamp, and an electric discharge lamp, the electric discharge lamp comprising at least one of xenon, argon, and mercury vapor.
19. The method of claim 12 , wherein the light source generates a quasi-continuous light with a frequency less than about 100 Hertz.
20. The method of claim 12 , wherein the inflammatory disease is at least one of
allergic rhinitis, vasomotor rhinitis, non-allergic rhinitis, rhinosinusitis, sinusitis, and nasal polyp.
21. The method of claim 12 , wherein the preparation for the application of the photoherapeutical apparatus comprises
determining at least one of a minimal erythema dosis.
22. The method of claim 21 , wherein the applying the light to the tissue surface of the body cavity comprises
applying the light in a dose calculated in relation to at least one of the minimal erythema dosis.
23. The method of claim 12 , wherein the preparation for the application of the photoherapeutical apparatus comprises
applying a photosensitizer substance to the tissue surface.
24. The method of claim 23 , wherein the photosensitizer substance is at least one of
a porphirin precursor, a metabolite of a porphirin precursor, and a synthetic photosensitizing compound, wherein
the photosensitizer substance becomes activated after the application of the generated light.
25. The method of claim 23 , wherein the applying the photosensitizer substance comprises
applying the photosensitizer substance to the tissue surface in a concentration between about 1% and about 20%.
26. A method of preventing diseases, the method comprising:
providing a phototherapeutical apparatus, comprising:
a light source, operable to generate high intensity visible light;
an optical guidance system, coupled to the light source; and
a patient interface, coupled to the optical guidance system;
preparing for the application of the phototherapeutical apparatus;
generating high intensity visible light with the light source;
coupling the high intensity visible light into the patient interface through the optical guidance system;
applying the high intensity visible light by the patient interface to a tissue surface of a nasal cavity, wherein
the tissue of the nasal cavity is symptom-free.
27. The method of claim 26 , wherein the applying the light by the patient interface comprises
inserting the patient interface at least partially into the nasal cavity.
28. The method of claim 26 , wherein the preventing diseases comprises
preventing at least one of an inflammatory disease and a hyper-proliferative disease.
29. The method of claim 26 , wherein the preventing diseases comprises
preventing a disease of at least one of a mucous membrane of a nasal cavity and a nasal sinus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/319,684 US20060111760A1 (en) | 2001-08-10 | 2005-12-28 | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0103279A HU224941B1 (en) | 2001-08-10 | 2001-08-10 | Phototerapy apparatus |
HUP0103279 | 2001-08-10 | ||
PCT/HU2001/000102 WO2003013653A1 (en) | 2001-08-10 | 2001-10-24 | Phototherapeutical apparatus |
US10/410,690 US7226470B2 (en) | 2001-08-10 | 2003-04-09 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2001/000102 Continuation-In-Part WO2003013653A1 (en) | 2001-08-10 | 2001-10-24 | Phototherapeutical apparatus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/319,684 Continuation US20060111760A1 (en) | 2001-08-10 | 2005-12-28 | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040030368A1 true US20040030368A1 (en) | 2004-02-12 |
Family
ID=89979613
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/410,690 Expired - Fee Related US7226470B2 (en) | 2001-08-10 | 2003-04-09 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
US10/440,690 Abandoned US20040030368A1 (en) | 2001-08-10 | 2003-05-19 | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa |
US11/319,684 Abandoned US20060111760A1 (en) | 2001-08-10 | 2005-12-28 | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa |
US11/354,364 Abandoned US20060136019A1 (en) | 2001-08-10 | 2006-02-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
US11/354,788 Abandoned US20060155349A1 (en) | 2001-08-10 | 2006-02-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
US11/453,736 Abandoned US20060235492A1 (en) | 2001-08-10 | 2006-06-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/410,690 Expired - Fee Related US7226470B2 (en) | 2001-08-10 | 2003-04-09 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/319,684 Abandoned US20060111760A1 (en) | 2001-08-10 | 2005-12-28 | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa |
US11/354,364 Abandoned US20060136019A1 (en) | 2001-08-10 | 2006-02-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
US11/354,788 Abandoned US20060155349A1 (en) | 2001-08-10 | 2006-02-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
US11/453,736 Abandoned US20060235492A1 (en) | 2001-08-10 | 2006-06-15 | Phototherapeutical apparatus and method for the treatment and prevention of diseases of body cavities |
Country Status (14)
Country | Link |
---|---|
US (6) | US7226470B2 (en) |
EP (1) | EP1420857B1 (en) |
JP (1) | JP4245476B2 (en) |
AT (1) | ATE430598T1 (en) |
AU (1) | AU2002214169B2 (en) |
CZ (1) | CZ2004177A3 (en) |
DE (1) | DE60138656D1 (en) |
ES (1) | ES2325058T3 (en) |
HU (1) | HU224941B1 (en) |
PL (1) | PL204588B1 (en) |
RU (1) | RU2290224C2 (en) |
SK (1) | SK287945B6 (en) |
UA (1) | UA84257C2 (en) |
WO (1) | WO2003013653A1 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040158301A1 (en) * | 2001-03-02 | 2004-08-12 | Kevin Tucek | Scanning treatment laser |
US20050090722A1 (en) * | 2003-09-17 | 2005-04-28 | Thomas Perez | Method and apparatus for providing UV light to blood |
US20050261621A1 (en) * | 2003-09-17 | 2005-11-24 | Thomas Perez | Method and apparatus for providing UV light to blood |
US20060074467A1 (en) * | 2003-09-17 | 2006-04-06 | Thomas Perez | Method and apparatus for sublingual application of light to blood |
US20060095102A1 (en) * | 2003-09-17 | 2006-05-04 | Thomas Perez | Method and apparatus for sublingual application of light to blood |
US20060095099A1 (en) * | 2004-02-04 | 2006-05-04 | Shanks Steven C | Stand-alone scanning laser device |
US20060111762A1 (en) * | 2004-11-20 | 2006-05-25 | Erasmus Medical Centre | Device and method for photodynamic therapy of the nasopharyngeal cavity |
US20060167531A1 (en) * | 2005-01-25 | 2006-07-27 | Michael Gertner | Optical therapies and devices |
US20060224218A1 (en) * | 2004-02-04 | 2006-10-05 | Kevin Tucek | Scanning treatment laser with sweep beam spot and universal carriage |
US20060222667A1 (en) * | 2003-05-13 | 2006-10-05 | The Foundry, Inc. | Apparatus for treating asthma using neurotoxin |
US20060259101A1 (en) * | 2005-05-10 | 2006-11-16 | Thomas Perez | UV light irradiation machine for veterinary use |
US20060287695A1 (en) * | 2005-06-16 | 2006-12-21 | Dimauro Thomas M | Intranasal red light probe for treating Alzheimer's disease |
US20060292182A1 (en) * | 2005-06-27 | 2006-12-28 | Lajos Kemeny | Photoadjuvant immunotherapy |
US20070010859A1 (en) * | 2005-07-07 | 2007-01-11 | Dimauro Thomas M | Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue |
US20070098645A1 (en) * | 2005-10-31 | 2007-05-03 | Agbodoe Victor B | Intranasal delivery of compounds that reduce intrancranial pressure |
US20070106339A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Electrical stimulation treatment of bronchial constriction |
US20070191902A1 (en) * | 2006-02-10 | 2007-08-16 | Electrocore, Inc. | Methods and apparatus for treating anaphylaxis using electrical modulation |
US20070191905A1 (en) * | 2006-02-10 | 2007-08-16 | Electrocore, Inc. | Electrical stimulation treatment of hypotension |
US20070206901A1 (en) * | 2006-03-02 | 2007-09-06 | Bonitatibus Michael H | Sunlight simulator apparatus |
US20070219600A1 (en) * | 2006-03-17 | 2007-09-20 | Michael Gertner | Devices and methods for targeted nasal phototherapy |
US20070239235A1 (en) * | 2005-03-14 | 2007-10-11 | Dimauro Thomas M | Red Light Implant For Treating Parkinson's Disease |
US20070255356A1 (en) * | 2006-04-28 | 2007-11-01 | Ondine International, Ltd. | Photodisinfection delivery devices and methods |
US20070285758A1 (en) * | 2004-01-27 | 2007-12-13 | Degeratu D Ion C | Medical apparatus with light flux for biological treatments |
US20080125837A1 (en) * | 2004-02-06 | 2008-05-29 | Therapy Products, Inc. | Noninvasive method for site-specific fat reduction with catalyst |
US20090132012A1 (en) * | 2007-11-16 | 2009-05-21 | Therapy Products, Inc. | Method for pretreating patient before surgery |
US20090187231A1 (en) * | 2005-11-10 | 2009-07-23 | Electrocore, Inc. | Electrical Treatment Of Bronchial Constriction |
US20090204111A1 (en) * | 2008-02-13 | 2009-08-13 | Alois Bissig | Light delivery device |
US20090306644A1 (en) * | 2008-05-09 | 2009-12-10 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US20100114261A1 (en) * | 2006-02-10 | 2010-05-06 | Electrocore Llc | Electrical Stimulation Treatment of Hypotension |
US20100198316A1 (en) * | 2009-02-04 | 2010-08-05 | Richard Toselli | Intracranial Red Light Treatment Device For Chronic Pain |
US20100196497A1 (en) * | 2009-02-02 | 2010-08-05 | Therapy Products, Inc. | Method of Treating Tissue Using Platelet-Rich Plasma in Combination with Low-Level Laser Therapy |
US20100241188A1 (en) * | 2009-03-20 | 2010-09-23 | Electrocore, Inc. | Percutaneous Electrical Treatment Of Tissue |
US20110125203A1 (en) * | 2009-03-20 | 2011-05-26 | ElectroCore, LLC. | Magnetic Stimulation Devices and Methods of Therapy |
US20110152855A1 (en) * | 2009-10-27 | 2011-06-23 | Mayse Martin L | Delivery devices with coolable energy emitting assemblies |
WO2011142632A2 (en) * | 2010-05-14 | 2011-11-17 | 주식회사 옵토웰 | Laser irradiator |
US20120245659A1 (en) * | 2009-08-25 | 2012-09-27 | Charles Joseph Matthews | Systems and methods for stimulation of neuronal activity |
US20130006334A1 (en) * | 2010-02-04 | 2013-01-03 | Mauro Galli | Device for the treatment of the vaginal canal and relevant equipment |
US20130035746A1 (en) * | 2011-08-05 | 2013-02-07 | Denis Bouboulis | Apparatus and method for treating rhinitis |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US20140207214A1 (en) * | 2010-08-05 | 2014-07-24 | Richard Oberreiter | Apparatus and methods for controlling and applying flash lamp radiation |
US8821559B2 (en) | 2004-08-27 | 2014-09-02 | Codman & Shurtleff, Inc. | Light-based implants for treating Alzheimer's disease |
US8840537B2 (en) | 2005-11-10 | 2014-09-23 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US9149328B2 (en) | 2009-11-11 | 2015-10-06 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US9320914B2 (en) | 2008-03-03 | 2016-04-26 | DePuy Synthes Products, Inc. | Endoscopic delivery of red/NIR light to the subventricular zone |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US20170266396A1 (en) * | 2016-03-21 | 2017-09-21 | Joseph Feldman | Nasal spray apparatus |
US10180248B2 (en) | 2015-09-02 | 2019-01-15 | ProPhotonix Limited | LED lamp with sensing capabilities |
USRE47266E1 (en) | 2005-03-14 | 2019-03-05 | DePuy Synthes Products, Inc. | Light-based implants for treating Alzheimer's disease |
EP3610921A1 (en) * | 2018-08-14 | 2020-02-19 | Metacine, Inc. | Rhinitis photo therapeutic device with a nasal probe using low-level laser based on diffusing light technology |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2525569A1 (en) * | 2003-05-24 | 2004-12-09 | Ledeep, Llc | Skin tanning and light therapy system and method |
US20050053895A1 (en) | 2003-09-09 | 2005-03-10 | The Procter & Gamble Company Attention: Chief Patent Counsel | Illuminated electric toothbrushes emitting high luminous intensity toothbrush |
US20050261622A1 (en) * | 2003-09-17 | 2005-11-24 | Thomas Perez | Method and apparatus for providing light to blood |
US7435252B2 (en) * | 2003-10-15 | 2008-10-14 | Valam Corporation | Control of microorganisms in the sino-nasal tract |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
EP1735054A4 (en) * | 2004-03-09 | 2010-01-20 | Ledeep Llc | Phototherapy systems and methods |
CA2563331A1 (en) * | 2004-04-12 | 2005-12-15 | Ledeep, Llc | Phototherapy systems and methods |
US7201767B2 (en) * | 2004-05-27 | 2007-04-10 | Bhullar Tarseam S | Device for ultraviolet radiation treatment of body tissues |
US20090222069A1 (en) * | 2005-11-16 | 2009-09-03 | Aalborg Universitet | Light modulation of cell function |
US20070203550A1 (en) * | 2006-02-27 | 2007-08-30 | Thomas Perez | Method and apparatus for application of light to tissue |
US8088122B2 (en) * | 2006-08-17 | 2012-01-03 | George Y. Choi | Optical ear infection treatment device and method |
US20080058903A1 (en) * | 2006-09-05 | 2008-03-06 | Morgan Robert D | Light conductor and treatment for ailments involving the throat |
JP4670780B2 (en) * | 2006-09-20 | 2011-04-13 | ウシオ電機株式会社 | Phototherapy device |
WO2008051918A2 (en) * | 2006-10-23 | 2008-05-02 | Allux Medical, Inc. | Methods, devices and kits for phototherapy and photodynamic therapy treatment of body cavities |
US20090093865A1 (en) * | 2006-11-28 | 2009-04-09 | Valam Inc. | Method and system for controlling the spread of microorganisms among subjects in a group |
WO2008136958A1 (en) * | 2007-04-30 | 2008-11-13 | Opthera, Inc. | Uva1-led phototherapy device and method |
EP2197546A1 (en) * | 2007-09-14 | 2010-06-23 | Light Sciences Oncology, Inc. | Systems, devices, and methods for photoactive assisted resection |
HU227936B1 (en) | 2009-03-28 | 2012-06-28 | Ventino Kft | Apparatus for venting no gas out of paranasal sinus |
US8721696B2 (en) | 2009-07-21 | 2014-05-13 | Valam Corporation | Selective treatments for chronic rhinosinusitis |
ES2440795T3 (en) * | 2011-01-12 | 2014-01-30 | Fotona D.D. | Laser system for non-ablative treatment of mucosal tissues |
RU2477160C1 (en) * | 2011-11-29 | 2013-03-10 | Владимир Иванович Семенников | Method of treating odontogenous maxillary sinusitis |
RU2499597C2 (en) * | 2012-02-07 | 2013-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия имени Н.Е. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Method of treating and preventing nasal obstruction in patients suffering polypous rhinosinusitis |
US9884202B2 (en) * | 2012-02-28 | 2018-02-06 | Koninklijke Philips N.V. | Device for light based skin treatment |
US9931187B2 (en) | 2012-04-05 | 2018-04-03 | Brad HECKERMAN | Photon induced acoustic streaming device and method |
WO2014164432A1 (en) * | 2013-03-13 | 2014-10-09 | Greenzapr, Inc. | Ultraviolet sanitizer with wand |
EP2969010B1 (en) | 2013-03-13 | 2017-10-11 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
US10201387B2 (en) | 2013-03-13 | 2019-02-12 | The Spectranetics Corporation | Laser-induced fluid filled balloon catheter |
US10842567B2 (en) | 2013-03-13 | 2020-11-24 | The Spectranetics Corporation | Laser-induced fluid filled balloon catheter |
KR20150135339A (en) | 2013-03-13 | 2015-12-02 | 인플래머토리 리스폰스 리서치, 아이엔씨. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
US9320530B2 (en) | 2013-03-13 | 2016-04-26 | The Spectranetics Corporation | Assisted cutting balloon |
JP6195268B2 (en) * | 2013-07-18 | 2017-09-13 | 国立大学法人徳島大学 | Rhinitis prevention and treatment equipment |
ITFI20130182A1 (en) * | 2013-08-01 | 2015-02-02 | El En Spa | "DEVICE FOR THE TREATMENT OF THE VAGINAL CHANNEL OR OTHER NATURAL ORIFICES OR SURGICAL-FINAL, AND ITS APPARATUS" |
WO2015048806A2 (en) | 2013-09-30 | 2015-04-02 | Nidus Medical, Llc | Apparatus and methods for treating rhinitis |
ITFI20130251A1 (en) * | 2013-10-22 | 2015-04-23 | El En Spa | "DEVICE FOR COMBINED TREATMENT THROUGH LASER RADIATION AND CURRENT RADIO FREQUENCY OF THE VAGINAL CHANNEL OR OTHER ORIFICES, AND ITS APPARATUS" |
CN104001273B (en) * | 2014-06-10 | 2016-08-17 | 武汉博激世纪科技有限公司 | A kind of pen type oral cavity laser therapeutic apparatus |
US9763743B2 (en) | 2014-07-25 | 2017-09-19 | Arrinex, Inc. | Apparatus and method for treating rhinitis |
RU2559593C1 (en) * | 2014-08-06 | 2015-08-10 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации | Method of treating active chronic inflammatory diseases of nasal sinus |
US11246659B2 (en) | 2014-08-25 | 2022-02-15 | The Spectranetics Corporation | Liquid laser-induced pressure wave emitting catheter sheath |
EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
WO2016109737A1 (en) | 2014-12-30 | 2016-07-07 | The Spectranetics Corporation | Electrically-induced fluid filled balloon catheter |
US11058492B2 (en) | 2014-12-30 | 2021-07-13 | The Spectranetics Corporation | Laser-induced pressure wave emitting catheter sheath |
EP3240600B1 (en) | 2014-12-30 | 2019-05-08 | The Spectranetics Corporation | Electrically-induced pressure wave emitting catheter sheath |
EP3328491A4 (en) | 2015-07-28 | 2019-05-01 | PhotonMD, Inc. | Systems and methods for phototherapeutic modulation of nitric oxide |
WO2017139805A1 (en) | 2016-02-11 | 2017-08-17 | Arrinex, Inc. | Method and device for image guided post-nasal nerve ablation |
WO2017178897A2 (en) | 2016-04-12 | 2017-10-19 | Arturo Solis Herrera | Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
EP3471638A4 (en) | 2016-06-15 | 2020-03-11 | Arrinex, Inc. | Devices and methods for treating a lateral surface of a nasal cavity |
US10939965B1 (en) | 2016-07-20 | 2021-03-09 | Arrinex, Inc. | Devices and methods for treating a nerve of the nasal cavity using image guidance |
US11253312B2 (en) | 2016-10-17 | 2022-02-22 | Arrinex, Inc. | Integrated nasal nerve detector ablation-apparatus, nasal nerve locator, and methods of use |
CN110891507B (en) | 2017-04-28 | 2023-06-23 | 阿里内克斯股份有限公司 | Systems and methods for locating blood vessels in the treatment of rhinitis |
US11896494B2 (en) | 2017-07-10 | 2024-02-13 | Life Spine, Inc. | Expandable implant assembly |
US20190192706A1 (en) * | 2017-12-22 | 2019-06-27 | Inikoa Medical, Inc. | Disinfecting Methods and Apparatus |
US11622805B2 (en) | 2018-06-08 | 2023-04-11 | Acclarent, Inc. | Apparatus and method for performing vidian neurectomy procedure |
US11786296B2 (en) | 2019-02-15 | 2023-10-17 | Accularent, Inc. | Instrument for endoscopic posterior nasal nerve ablation |
US11534235B2 (en) | 2019-04-04 | 2022-12-27 | Acclarent, Inc. | Needle instrument for posterior nasal neurectomy ablation |
CN110123247B (en) * | 2019-04-09 | 2021-12-28 | 苏州西能捷科技发展有限公司 | Nasosinusitis detection system |
CN110404180A (en) * | 2019-08-28 | 2019-11-05 | 武汉优瑞科技有限公司 | A kind of photon therapeutic equipment for nose treatment |
US20210196974A1 (en) * | 2019-12-31 | 2021-07-01 | Gyrus Acmi, Inc. D/B/A Olympus Surgical Technologies America | Surgical devices for treating body tissue and diagnosing patients |
US11147984B2 (en) | 2020-03-19 | 2021-10-19 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11857432B2 (en) | 2020-04-13 | 2024-01-02 | Life Spine, Inc. | Expandable implant assembly |
US11602439B2 (en) | 2020-04-16 | 2023-03-14 | Life Spine, Inc. | Expandable implant assembly |
IL298600A (en) * | 2020-06-01 | 2023-01-01 | Avalo Therapeutics Inc | Methods and treatment involving antibodies to il-18 |
US11602440B2 (en) | 2020-06-25 | 2023-03-14 | Life Spine, Inc. | Expandable implant assembly |
US11806558B2 (en) | 2020-06-26 | 2023-11-07 | Clear Blew | Body-worn air-treatment devices and methods of deactivating pathogens |
US11654294B2 (en) | 2021-03-15 | 2023-05-23 | Know Bio, Llc | Intranasal illumination devices |
GB2607338B (en) * | 2021-06-03 | 2023-10-18 | Gyrus Medical Ltd | Ultraviolet instrument |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765322A (en) * | 1984-05-21 | 1988-08-23 | Symtonic Sa | Method of treating neurovegetative disorders and apparatus therefor |
US4842356A (en) * | 1987-04-15 | 1989-06-27 | Kei Mori | Light ray radiation device for use in medical treatment of the nose and throat passages |
US5292346A (en) * | 1992-02-20 | 1994-03-08 | Ceravolo Frank J | Bactericidal throat gun |
US5344433A (en) * | 1991-11-28 | 1994-09-06 | Dimotech Ltd. | Apparatus for the treatment of skin wounds |
US5405368A (en) * | 1992-10-20 | 1995-04-11 | Esc Inc. | Method and apparatus for therapeutic electromagnetic treatment |
US5445608A (en) * | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5620478A (en) * | 1992-10-20 | 1997-04-15 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5626631A (en) * | 1992-10-20 | 1997-05-06 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5720772A (en) * | 1992-10-20 | 1998-02-24 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5843143A (en) * | 1992-10-23 | 1998-12-01 | Cancer Research Campaign Technology Ltd. | Light source |
US5855595A (en) * | 1994-04-04 | 1999-01-05 | Asahi Kogaku Kogyo Kabushiki Kaisha | Tumor treatment apparatus |
US5919217A (en) * | 1987-12-08 | 1999-07-06 | Medic-Light, Inc. | Portable phototherapy unit |
US5925034A (en) * | 1994-08-23 | 1999-07-20 | Sisters Of Providence In Oregon | Method and apparatus for determination of psoralen concentrations in biological tissues |
US5989283A (en) * | 1996-09-26 | 1999-11-23 | Heinrike Wilkens | Irradiation device, especially for the cosmetic, diagnostic and therapeutic application of light |
US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
US6413268B1 (en) * | 2000-08-11 | 2002-07-02 | Raymond A. Hartman | Apparatus and method for targeted UV phototherapy of skin disorders |
US6436127B1 (en) * | 1997-10-08 | 2002-08-20 | The General Hospital Corporation | Phototherapy methods and systems |
US6447537B1 (en) * | 2000-06-21 | 2002-09-10 | Raymond A. Hartman | Targeted UV phototherapy apparatus and method |
US20020161418A1 (en) * | 2001-03-08 | 2002-10-31 | Wilkens Jan Hennrik | Irradiation device |
US6530919B1 (en) * | 1998-10-30 | 2003-03-11 | Redfield, Inc. | Infrared coagulator with disposable tip light guide |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1800277A (en) * | 1925-05-28 | 1931-04-14 | Edward W Boerstler | Method for producing therapeutic rays |
US1616722A (en) * | 1926-06-12 | 1927-02-08 | Fred G Vernon | Kromayer-light attachment |
US1677016A (en) * | 1926-07-01 | 1928-07-10 | Gen Electric | Quartz applicator |
US1782906A (en) * | 1929-10-10 | 1930-11-25 | Morris S Newman | Device for treating the stomach with ultra-violet rays |
US2227422A (en) * | 1938-01-17 | 1941-01-07 | Edward W Boerstler | Applicator for use in treatment with therapeutic rays |
US3693623A (en) * | 1970-12-25 | 1972-09-26 | Gregory System Inc | Photocoagulation means and method for depilation |
US4313431A (en) | 1978-12-06 | 1982-02-02 | Messerschmitt-Boelkow-Blohm Gesellschaft Mit Beschraenkter Haftung | Endoscopic apparatus with a laser light conductor |
DE3323365C2 (en) | 1982-09-04 | 1994-10-20 | Gsf Forschungszentrum Umwelt | Method and device for illuminating cavities |
WO1985002101A1 (en) * | 1983-11-08 | 1985-05-23 | Laserscope, Inc. | Endoscopic device having handle assembly and catheter assembly |
US4686979A (en) | 1984-01-09 | 1987-08-18 | The United States Of America As Represented By The United States Department Of Energy | Excimer laser phototherapy for the dissolution of abnormal growth |
JPH0741082B2 (en) | 1984-09-14 | 1995-05-10 | オリンパス光学工業株式会社 | Laser probe |
US4830460A (en) * | 1987-05-19 | 1989-05-16 | Advanced Interventional Systems, Inc. | Guidance system and method for delivery system for high-energy pulsed ultraviolet laser light |
US5104392A (en) * | 1985-03-22 | 1992-04-14 | Massachusetts Institute Of Technology | Laser spectro-optic imaging for diagnosis and treatment of diseased tissue |
US4862886A (en) | 1985-05-08 | 1989-09-05 | Summit Technology Inc. | Laser angioplasty |
JP2519701B2 (en) * | 1987-01-14 | 1996-07-31 | 住友電気工業株式会社 | UV sterilizer |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US4782819A (en) | 1987-02-25 | 1988-11-08 | Adair Edwin Lloyd | Optical catheter |
US4878891A (en) * | 1987-06-25 | 1989-11-07 | Baylor Research Foundation | Method for eradicating infectious biological contaminants in body tissues |
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
US4998930A (en) | 1988-08-03 | 1991-03-12 | Phototherapeutic Systems | Intracavity laser phototherapy method |
US4899732A (en) * | 1988-09-02 | 1990-02-13 | Baxter International, Inc. | Miniscope |
US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
US5422093A (en) * | 1989-07-28 | 1995-06-06 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
DE3932030A1 (en) * | 1989-09-26 | 1991-04-04 | Philips Patentverwaltung | HIGH PRESSURE GAS DISCHARGE LAMP |
DE3941706C1 (en) | 1989-12-18 | 1991-02-28 | Gesellschaft Fuer Strahlen- Und Umweltforschung Mbh, 8042 Neuherberg, De | |
EP0435506A3 (en) * | 1989-12-19 | 1991-08-14 | Pfizer Hospital Products Group, Inc. | Infrared delivery system with aiming component |
EP0437182B1 (en) | 1990-01-09 | 1995-01-18 | Ciba-Geigy Ag | Fibre optic apparatus for the photodynamic treatment of tumours |
US5981163A (en) * | 1990-05-15 | 1999-11-09 | New York Blood Center, Inc. | Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions |
US5232844A (en) * | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
DE9104584U1 (en) * | 1991-04-15 | 1991-06-06 | Patent-Treuhand-Gesellschaft Fuer Elektrische Gluehlampen Mbh, 8000 Muenchen, De | |
US5344418A (en) * | 1991-12-12 | 1994-09-06 | Shahriar Ghaffari | Optical system for treatment of vascular lesions |
US5439462A (en) | 1992-02-25 | 1995-08-08 | Intelligent Surgical Lasers | Apparatus for removing cataractous material |
US5235045A (en) * | 1992-03-19 | 1993-08-10 | Microbiomed Corporation | Non-azo naphthalimide dyes |
WO1993018715A1 (en) * | 1992-03-20 | 1993-09-30 | The General Hospital Corporation | Laser illuminator |
US5239230A (en) * | 1992-03-27 | 1993-08-24 | General Electric Company | High brightness discharge light source |
DE4320579C2 (en) * | 1992-06-15 | 2000-06-15 | Topcon Corp | Surgical microscope |
RU2045971C1 (en) | 1993-01-13 | 1995-10-20 | Обособленное научно-исследовательское подразделение по солнечной и точной оптике при Научно-производственном объединении "Астрофизика" | Irradiating apparatus |
US6251100B1 (en) * | 1993-09-24 | 2001-06-26 | Transmedica International, Inc. | Laser assisted topical anesthetic permeation |
TW323379B (en) * | 1994-01-18 | 1997-12-21 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | |
IL108772A0 (en) * | 1994-02-24 | 1994-05-30 | Amcor Ltd | Treatment of rhinitis by biostimulative illumination |
CA2199384C (en) | 1994-09-09 | 2006-06-06 | Edward L. Sinofsky | Phototherapeutic apparatus |
DE29508077U1 (en) * | 1995-05-16 | 1995-08-10 | Wilden Lutz Dr Med | Oral care device |
US6238391B1 (en) * | 1995-06-07 | 2001-05-29 | Arthrocare Corporation | Systems for tissue resection, ablation and aspiration |
US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
AU5431898A (en) * | 1996-11-21 | 1998-06-10 | Boston Scientific Corporation | Mucosal ablation using light |
WO1999004628A1 (en) * | 1997-07-28 | 1999-02-04 | Dermatolazer Technologies Ltd. | Phototherapy based method for treating pathogens and composition for effecting same |
US6071302A (en) | 1997-12-31 | 2000-06-06 | Cardiofocus, Inc. | Phototherapeutic apparatus for wide-angle diffusion |
US5976124A (en) | 1998-01-05 | 1999-11-02 | Spectranetics Corporation | Phototherapy device and method |
DE19846580A1 (en) * | 1998-08-21 | 2000-04-06 | Guenther Nath | Handpiece with switch and optical cable used to polymerize dental materials employs ring magnet to operate reed switch without hindering rotation of handpiece |
US6376988B1 (en) * | 1998-08-28 | 2002-04-23 | Matsushita Electric Industrial Co., Ltd. | Discharge lamp for automobile headlight and the automobile headlight |
US6511971B1 (en) * | 1998-10-13 | 2003-01-28 | Brown University Research Foundation | Substituted perhalogenated phthalocyanines |
DE19954710C1 (en) * | 1999-11-17 | 2001-03-15 | Pulsion Medical Sys Ag | Apparatus for treatment of blood vessels especially in eye, comprises laser to deliver structured beam and monitor system to measure concentration of chromophoric agents for system control |
RU2169022C1 (en) | 1999-12-14 | 2001-06-20 | Давыдкин Александр Федорович | Device for ultraviolet blood irradiation |
US6692486B2 (en) * | 2000-05-10 | 2004-02-17 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of cerebral aneurysms, arterial-vascular malformations and arterial fistulas |
US6551346B2 (en) * | 2000-05-17 | 2003-04-22 | Kent Crossley | Method and apparatus to prevent infections |
JP2002011106A (en) * | 2000-06-28 | 2002-01-15 | Nidek Co Ltd | Laser therapeutic apparatus |
US7019376B2 (en) * | 2000-08-11 | 2006-03-28 | Reflectivity, Inc | Micromirror array device with a small pitch size |
AU2002245163A1 (en) * | 2000-10-20 | 2002-07-24 | Photomedex | Controlled dose delivery of ultraviolet light for treating skin disorders |
-
2001
- 2001-08-10 HU HU0103279A patent/HU224941B1/en not_active IP Right Cessation
- 2001-10-24 SK SK87-2004A patent/SK287945B6/en not_active IP Right Cessation
- 2001-10-24 AU AU2002214169A patent/AU2002214169B2/en not_active Ceased
- 2001-10-24 DE DE60138656T patent/DE60138656D1/en not_active Expired - Lifetime
- 2001-10-24 RU RU2004104624/14A patent/RU2290224C2/en not_active IP Right Cessation
- 2001-10-24 WO PCT/HU2001/000102 patent/WO2003013653A1/en active Application Filing
- 2001-10-24 UA UA2004031506A patent/UA84257C2/en unknown
- 2001-10-24 JP JP2003518652A patent/JP4245476B2/en not_active Expired - Fee Related
- 2001-10-24 AT AT01982627T patent/ATE430598T1/en not_active IP Right Cessation
- 2001-10-24 EP EP01982627A patent/EP1420857B1/en not_active Expired - Lifetime
- 2001-10-24 PL PL374004A patent/PL204588B1/en not_active IP Right Cessation
- 2001-10-24 ES ES01982627T patent/ES2325058T3/en not_active Expired - Lifetime
- 2001-10-24 CZ CZ2004177A patent/CZ2004177A3/en unknown
-
2003
- 2003-04-09 US US10/410,690 patent/US7226470B2/en not_active Expired - Fee Related
- 2003-05-19 US US10/440,690 patent/US20040030368A1/en not_active Abandoned
-
2005
- 2005-12-28 US US11/319,684 patent/US20060111760A1/en not_active Abandoned
-
2006
- 2006-02-15 US US11/354,364 patent/US20060136019A1/en not_active Abandoned
- 2006-02-15 US US11/354,788 patent/US20060155349A1/en not_active Abandoned
- 2006-06-15 US US11/453,736 patent/US20060235492A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765322A (en) * | 1984-05-21 | 1988-08-23 | Symtonic Sa | Method of treating neurovegetative disorders and apparatus therefor |
US4842356A (en) * | 1987-04-15 | 1989-06-27 | Kei Mori | Light ray radiation device for use in medical treatment of the nose and throat passages |
US5919217A (en) * | 1987-12-08 | 1999-07-06 | Medic-Light, Inc. | Portable phototherapy unit |
US5344433A (en) * | 1991-11-28 | 1994-09-06 | Dimotech Ltd. | Apparatus for the treatment of skin wounds |
US5292346A (en) * | 1992-02-20 | 1994-03-08 | Ceravolo Frank J | Bactericidal throat gun |
US5405368A (en) * | 1992-10-20 | 1995-04-11 | Esc Inc. | Method and apparatus for therapeutic electromagnetic treatment |
US6174325B1 (en) * | 1992-10-20 | 2001-01-16 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5620478A (en) * | 1992-10-20 | 1997-04-15 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5626631A (en) * | 1992-10-20 | 1997-05-06 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5720772A (en) * | 1992-10-20 | 1998-02-24 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5755751A (en) * | 1992-10-20 | 1998-05-26 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5843143A (en) * | 1992-10-23 | 1998-12-01 | Cancer Research Campaign Technology Ltd. | Light source |
US5445608A (en) * | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5855595A (en) * | 1994-04-04 | 1999-01-05 | Asahi Kogaku Kogyo Kabushiki Kaisha | Tumor treatment apparatus |
US5925034A (en) * | 1994-08-23 | 1999-07-20 | Sisters Of Providence In Oregon | Method and apparatus for determination of psoralen concentrations in biological tissues |
US5989283A (en) * | 1996-09-26 | 1999-11-23 | Heinrike Wilkens | Irradiation device, especially for the cosmetic, diagnostic and therapeutic application of light |
US6436127B1 (en) * | 1997-10-08 | 2002-08-20 | The General Hospital Corporation | Phototherapy methods and systems |
US6530919B1 (en) * | 1998-10-30 | 2003-03-11 | Redfield, Inc. | Infrared coagulator with disposable tip light guide |
US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
US6447537B1 (en) * | 2000-06-21 | 2002-09-10 | Raymond A. Hartman | Targeted UV phototherapy apparatus and method |
US6413268B1 (en) * | 2000-08-11 | 2002-07-02 | Raymond A. Hartman | Apparatus and method for targeted UV phototherapy of skin disorders |
US20020161418A1 (en) * | 2001-03-08 | 2002-10-31 | Wilkens Jan Hennrik | Irradiation device |
Cited By (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040158301A1 (en) * | 2001-03-02 | 2004-08-12 | Kevin Tucek | Scanning treatment laser |
US7118588B2 (en) * | 2001-03-02 | 2006-10-10 | Kevin Tucek | Scanning treatment laser |
US20060222667A1 (en) * | 2003-05-13 | 2006-10-05 | The Foundry, Inc. | Apparatus for treating asthma using neurotoxin |
US10953170B2 (en) | 2003-05-13 | 2021-03-23 | Nuvaira, Inc. | Apparatus for treating asthma using neurotoxin |
US9339618B2 (en) | 2003-05-13 | 2016-05-17 | Holaira, Inc. | Method and apparatus for controlling narrowing of at least one airway |
US8172827B2 (en) | 2003-05-13 | 2012-05-08 | Innovative Pulmonary Solutions, Inc. | Apparatus for treating asthma using neurotoxin |
US20070021640A1 (en) * | 2003-09-17 | 2007-01-25 | Thomas Perez | Method and apparatus for application of light to gums |
US20050261621A1 (en) * | 2003-09-17 | 2005-11-24 | Thomas Perez | Method and apparatus for providing UV light to blood |
US20060009821A1 (en) * | 2003-09-17 | 2006-01-12 | Thomas Perez | Method and apparatus for providing light to blood |
US20060074467A1 (en) * | 2003-09-17 | 2006-04-06 | Thomas Perez | Method and apparatus for sublingual application of light to blood |
WO2006130401A3 (en) * | 2003-09-17 | 2010-01-28 | Thomas Perez | Method and apparatus for providing light to blood |
WO2006130401A2 (en) * | 2003-09-17 | 2006-12-07 | Thomas Perez | Method and apparatus for providing light to blood |
US20060095102A1 (en) * | 2003-09-17 | 2006-05-04 | Thomas Perez | Method and apparatus for sublingual application of light to blood |
US20050090722A1 (en) * | 2003-09-17 | 2005-04-28 | Thomas Perez | Method and apparatus for providing UV light to blood |
US20070285758A1 (en) * | 2004-01-27 | 2007-12-13 | Degeratu D Ion C | Medical apparatus with light flux for biological treatments |
US7922751B2 (en) | 2004-02-04 | 2011-04-12 | Erchonia Corporation | Stand-alone scanning laser device |
US20060224218A1 (en) * | 2004-02-04 | 2006-10-05 | Kevin Tucek | Scanning treatment laser with sweep beam spot and universal carriage |
US7947067B2 (en) | 2004-02-04 | 2011-05-24 | Erchonia Corporation | Scanning treatment laser with sweep beam spot and universal carriage |
US20060095099A1 (en) * | 2004-02-04 | 2006-05-04 | Shanks Steven C | Stand-alone scanning laser device |
US20080125837A1 (en) * | 2004-02-06 | 2008-05-29 | Therapy Products, Inc. | Noninvasive method for site-specific fat reduction with catalyst |
US8821559B2 (en) | 2004-08-27 | 2014-09-02 | Codman & Shurtleff, Inc. | Light-based implants for treating Alzheimer's disease |
US7763058B2 (en) * | 2004-11-20 | 2010-07-27 | Dick Sterenborg | Device and method for photodynamic therapy of the nasopharyngeal cavity |
US20060111762A1 (en) * | 2004-11-20 | 2006-05-25 | Erasmus Medical Centre | Device and method for photodynamic therapy of the nasopharyngeal cavity |
US20060271024A1 (en) * | 2005-01-25 | 2006-11-30 | Michael Gertner | Nasal Cavity Treatment Apparatus |
US20080208297A1 (en) * | 2005-01-25 | 2008-08-28 | Allux Medical, Inc. | Optical Therapy Devices, Systems, Kits and Methods for Providing Therapy to a body Cavity |
US8109981B2 (en) * | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
US20060195165A1 (en) * | 2005-01-25 | 2006-08-31 | Michael Gertner | Optical therapy devices, systems, kits and methods for providing therapy to a body cavity |
US20060167531A1 (en) * | 2005-01-25 | 2006-07-27 | Michael Gertner | Optical therapies and devices |
US8900284B2 (en) | 2005-03-14 | 2014-12-02 | DePuy Synthes Products, LLC | Red light implant for treating Parkinson's disease |
US20070239235A1 (en) * | 2005-03-14 | 2007-10-11 | Dimauro Thomas M | Red Light Implant For Treating Parkinson's Disease |
USRE47266E1 (en) | 2005-03-14 | 2019-03-05 | DePuy Synthes Products, Inc. | Light-based implants for treating Alzheimer's disease |
US20060259101A1 (en) * | 2005-05-10 | 2006-11-16 | Thomas Perez | UV light irradiation machine for veterinary use |
US20110022130A1 (en) * | 2005-06-16 | 2011-01-27 | Dimauro Thomas M | Intranasal Red Light Probe For Treating Alzheimer's Disease |
US8734498B2 (en) | 2005-06-16 | 2014-05-27 | DePuy Synthes Products, LLC | Intranasal red light probe for treating alzheimer's disease |
US20060287695A1 (en) * | 2005-06-16 | 2006-12-21 | Dimauro Thomas M | Intranasal red light probe for treating Alzheimer's disease |
US7351253B2 (en) | 2005-06-16 | 2008-04-01 | Codman & Shurtleff, Inc. | Intranasal red light probe for treating Alzheimer's disease |
WO2006138659A3 (en) * | 2005-06-16 | 2007-03-01 | Codman & Shurtleff | Intranasal red light probe for treating alzheimers disease |
WO2006138659A2 (en) * | 2005-06-16 | 2006-12-28 | Codman & Shurtleff, Inc. | Intranasal red light probe for treating alzheimers disease |
US20060292182A1 (en) * | 2005-06-27 | 2006-12-28 | Lajos Kemeny | Photoadjuvant immunotherapy |
US20070010859A1 (en) * | 2005-07-07 | 2007-01-11 | Dimauro Thomas M | Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue |
US7939078B2 (en) | 2005-07-07 | 2011-05-10 | Codman & Shurtleff | Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue |
US20070098645A1 (en) * | 2005-10-31 | 2007-05-03 | Agbodoe Victor B | Intranasal delivery of compounds that reduce intrancranial pressure |
US8167920B2 (en) | 2005-10-31 | 2012-05-01 | Codman & Shurtleff, Inc. | Intranasal delivery of compounds that reduce intrancranial pressure |
US20090281593A9 (en) * | 2005-11-10 | 2009-11-12 | Electrocore, Inc. | Electrical Treatment Of Bronchial Constriction |
US8812112B2 (en) | 2005-11-10 | 2014-08-19 | ElectroCore, LLC | Electrical treatment of bronchial constriction |
US20070106339A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Electrical stimulation treatment of bronchial constriction |
US8840537B2 (en) | 2005-11-10 | 2014-09-23 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
US9037247B2 (en) | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
US7747324B2 (en) | 2005-11-10 | 2010-06-29 | Electrocore Llc | Electrical stimulation treatment of bronchial constriction |
US20100042178A9 (en) * | 2005-11-10 | 2010-02-18 | Electrocore, Inc. | Electrical stimulation treatment of bronchial constriction |
US20090187231A1 (en) * | 2005-11-10 | 2009-07-23 | Electrocore, Inc. | Electrical Treatment Of Bronchial Constriction |
US8233988B2 (en) | 2006-02-10 | 2012-07-31 | Electrocore Llc | Electrical stimulation treatment of hypotension |
US8041428B2 (en) | 2006-02-10 | 2011-10-18 | Electrocore Llc | Electrical stimulation treatment of hypotension |
US7869879B2 (en) | 2006-02-10 | 2011-01-11 | Electrocore Llc | Electrical stimulation treatment of hypotension |
US20100114261A1 (en) * | 2006-02-10 | 2010-05-06 | Electrocore Llc | Electrical Stimulation Treatment of Hypotension |
US8612004B2 (en) | 2006-02-10 | 2013-12-17 | ElectroCore, LLC | Electrical stimulation treatment of hypotension |
US7725188B2 (en) | 2006-02-10 | 2010-05-25 | Electrocore Llc | Electrical stimulation treatment of hypotension |
US7711430B2 (en) | 2006-02-10 | 2010-05-04 | Electrocore Llc | Methods and apparatus for treating anaphylaxis using electrical modulation |
US8099167B1 (en) | 2006-02-10 | 2012-01-17 | Electrocore Llc | Methods and apparatus for treating anaphylaxis using electrical modulation |
US8483835B2 (en) | 2006-02-10 | 2013-07-09 | ElectroCore, LLC | Methods and apparatus for treating anaphylaxis using electrical modulation |
US8010197B2 (en) | 2006-02-10 | 2011-08-30 | Electrocore Llc | Methods and apparatus for treating anaphylaxis using electrical modulation |
US20070191905A1 (en) * | 2006-02-10 | 2007-08-16 | Electrocore, Inc. | Electrical stimulation treatment of hypotension |
US20070191902A1 (en) * | 2006-02-10 | 2007-08-16 | Electrocore, Inc. | Methods and apparatus for treating anaphylaxis using electrical modulation |
US8204598B2 (en) | 2006-02-10 | 2012-06-19 | Electrocore Llc | Methods and apparatus for treating bronchial restriction using electrical modulation |
US20100158462A1 (en) * | 2006-03-02 | 2010-06-24 | Bonitatibus Michael H | Sunlight Simulator Apparatus |
US20070206901A1 (en) * | 2006-03-02 | 2007-09-06 | Bonitatibus Michael H | Sunlight simulator apparatus |
US7657147B2 (en) * | 2006-03-02 | 2010-02-02 | Solar Light Company, Inc. | Sunlight simulator apparatus |
US20070219600A1 (en) * | 2006-03-17 | 2007-09-20 | Michael Gertner | Devices and methods for targeted nasal phototherapy |
WO2007109496A2 (en) * | 2006-03-17 | 2007-09-27 | Allux Medical, Inc. | Devices and methods for targeted nasal phototherapy |
WO2007109496A3 (en) * | 2006-03-17 | 2008-02-21 | Allux Medical Inc | Devices and methods for targeted nasal phototherapy |
US20070255356A1 (en) * | 2006-04-28 | 2007-11-01 | Ondine International, Ltd. | Photodisinfection delivery devices and methods |
US20090132012A1 (en) * | 2007-11-16 | 2009-05-21 | Therapy Products, Inc. | Method for pretreating patient before surgery |
US9067059B2 (en) * | 2008-02-13 | 2015-06-30 | Alois Bissig | Light delivery device |
US20090204111A1 (en) * | 2008-02-13 | 2009-08-13 | Alois Bissig | Light delivery device |
US11058879B2 (en) | 2008-02-15 | 2021-07-13 | Nuvaira, Inc. | System and method for bronchial dilation |
US9125643B2 (en) | 2008-02-15 | 2015-09-08 | Holaira, Inc. | System and method for bronchial dilation |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8489192B1 (en) | 2008-02-15 | 2013-07-16 | Holaira, Inc. | System and method for bronchial dilation |
US8731672B2 (en) | 2008-02-15 | 2014-05-20 | Holaira, Inc. | System and method for bronchial dilation |
US9320914B2 (en) | 2008-03-03 | 2016-04-26 | DePuy Synthes Products, Inc. | Endoscopic delivery of red/NIR light to the subventricular zone |
US10561857B2 (en) | 2008-03-03 | 2020-02-18 | DePuy Synthes Products, Inc. | Method of treating traumatic brain injury with red/NIR light |
US8088127B2 (en) | 2008-05-09 | 2012-01-03 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8961507B2 (en) | 2008-05-09 | 2015-02-24 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US11937868B2 (en) | 2008-05-09 | 2024-03-26 | Nuvaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US20090306644A1 (en) * | 2008-05-09 | 2009-12-10 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8808280B2 (en) | 2008-05-09 | 2014-08-19 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8821489B2 (en) | 2008-05-09 | 2014-09-02 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US10149714B2 (en) | 2008-05-09 | 2018-12-11 | Nuvaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US9668809B2 (en) | 2008-05-09 | 2017-06-06 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8226638B2 (en) | 2008-05-09 | 2012-07-24 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US8961508B2 (en) | 2008-05-09 | 2015-02-24 | Holaira, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
US20100196497A1 (en) * | 2009-02-02 | 2010-08-05 | Therapy Products, Inc. | Method of Treating Tissue Using Platelet-Rich Plasma in Combination with Low-Level Laser Therapy |
US20100198316A1 (en) * | 2009-02-04 | 2010-08-05 | Richard Toselli | Intracranial Red Light Treatment Device For Chronic Pain |
US20100241188A1 (en) * | 2009-03-20 | 2010-09-23 | Electrocore, Inc. | Percutaneous Electrical Treatment Of Tissue |
US20110125203A1 (en) * | 2009-03-20 | 2011-05-26 | ElectroCore, LLC. | Magnetic Stimulation Devices and Methods of Therapy |
US20120245659A1 (en) * | 2009-08-25 | 2012-09-27 | Charles Joseph Matthews | Systems and methods for stimulation of neuronal activity |
US10118049B2 (en) * | 2009-08-25 | 2018-11-06 | Argus Neurooptics Llc | Systems and methods for stimulation of neuronal activity |
US8740895B2 (en) | 2009-10-27 | 2014-06-03 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8777943B2 (en) | 2009-10-27 | 2014-07-15 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8932289B2 (en) | 2009-10-27 | 2015-01-13 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9675412B2 (en) | 2009-10-27 | 2017-06-13 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US20110152855A1 (en) * | 2009-10-27 | 2011-06-23 | Mayse Martin L | Delivery devices with coolable energy emitting assemblies |
US9931162B2 (en) | 2009-10-27 | 2018-04-03 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9005195B2 (en) | 2009-10-27 | 2015-04-14 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9017324B2 (en) | 2009-10-27 | 2015-04-28 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9649153B2 (en) | 2009-10-27 | 2017-05-16 | Holaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US9649154B2 (en) | 2009-11-11 | 2017-05-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US10610283B2 (en) | 2009-11-11 | 2020-04-07 | Nuvaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US11389233B2 (en) | 2009-11-11 | 2022-07-19 | Nuvaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US9149328B2 (en) | 2009-11-11 | 2015-10-06 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US11712283B2 (en) | 2009-11-11 | 2023-08-01 | Nuvaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
US20130006334A1 (en) * | 2010-02-04 | 2013-01-03 | Mauro Galli | Device for the treatment of the vaginal canal and relevant equipment |
WO2011142632A2 (en) * | 2010-05-14 | 2011-11-17 | 주식회사 옵토웰 | Laser irradiator |
WO2011142632A3 (en) * | 2010-05-14 | 2012-04-19 | 주식회사 옵토웰 | Laser irradiator |
US10881872B1 (en) * | 2010-08-05 | 2021-01-05 | Richard Oberreiter | Apparatus and methods for controlling and applying flash lamp radiation |
US9744375B2 (en) * | 2010-08-05 | 2017-08-29 | Allergia, Inc. | Apparatus and methods for controlling and applying flash lamp radiation |
US20140207214A1 (en) * | 2010-08-05 | 2014-07-24 | Richard Oberreiter | Apparatus and methods for controlling and applying flash lamp radiation |
US10463872B2 (en) * | 2011-08-05 | 2019-11-05 | Lumimed, Llc | Device and method for treating allergic rhinitis |
US20160166848A1 (en) * | 2011-08-05 | 2016-06-16 | Lumimed, Llc | Device and method for treating allergic rhinitis |
US20130035746A1 (en) * | 2011-08-05 | 2013-02-07 | Denis Bouboulis | Apparatus and method for treating rhinitis |
US9265967B2 (en) * | 2011-08-05 | 2016-02-23 | Lumimed, Llc | Apparatus and method for treating rhinitis |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US10180248B2 (en) | 2015-09-02 | 2019-01-15 | ProPhotonix Limited | LED lamp with sensing capabilities |
US20170266396A1 (en) * | 2016-03-21 | 2017-09-21 | Joseph Feldman | Nasal spray apparatus |
CN110812709A (en) * | 2018-08-14 | 2020-02-21 | 昧打伸株式会社 | Rhinitis treatment device provided with nasal probe employing light diffusion technology of low-power laser |
EP3610921A1 (en) * | 2018-08-14 | 2020-02-19 | Metacine, Inc. | Rhinitis photo therapeutic device with a nasal probe using low-level laser based on diffusing light technology |
Also Published As
Publication number | Publication date |
---|---|
ATE430598T1 (en) | 2009-05-15 |
US20060235492A1 (en) | 2006-10-19 |
HUP0103279A2 (en) | 2003-04-28 |
CZ2004177A3 (en) | 2004-05-12 |
SK872004A3 (en) | 2004-08-03 |
US7226470B2 (en) | 2007-06-05 |
US20060155349A1 (en) | 2006-07-13 |
RU2290224C2 (en) | 2006-12-27 |
EP1420857A1 (en) | 2004-05-26 |
US20060136019A1 (en) | 2006-06-22 |
JP2004537382A (en) | 2004-12-16 |
US20060111760A1 (en) | 2006-05-25 |
RU2004104624A (en) | 2005-03-10 |
JP4245476B2 (en) | 2009-03-25 |
WO2003013653A1 (en) | 2003-02-20 |
US20040204747A1 (en) | 2004-10-14 |
SK287945B6 (en) | 2012-06-04 |
AU2002214169B2 (en) | 2007-07-12 |
DE60138656D1 (en) | 2009-06-18 |
PL374004A1 (en) | 2005-09-19 |
HU0103279D0 (en) | 2001-10-28 |
PL204588B1 (en) | 2010-01-29 |
ES2325058T3 (en) | 2009-08-25 |
UA84257C2 (en) | 2008-10-10 |
EP1420857B1 (en) | 2009-05-06 |
HU224941B1 (en) | 2006-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040030368A1 (en) | Phototherapeutical method and system for the treatment of inflammatory and hyperproliferative disorders of the nasal mucosa | |
AU2002214169A1 (en) | Phototherapeutical apparatus | |
Benson Jr et al. | Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy | |
JP3648555B2 (en) | Improved phototherapy device for irradiating a columnar environment | |
Gluckman | Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5‐year experience | |
Hürlimann et al. | Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion | |
US9744375B2 (en) | Apparatus and methods for controlling and applying flash lamp radiation | |
JP2001519217A (en) | Electromagnetic radiation therapy | |
US9034023B2 (en) | Dynamic colorectal PDT application | |
Morita et al. | Recent developments in phototherapy: treatment methods and devices | |
Waidelich | Laser-induced lithotripsy and photodynamic therapy in urology–A short introduction to current laser applications | |
RU2180604C2 (en) | Method for treatment of patients suffering chronic generalized parodontitis | |
Spinelli et al. | Endoscopic photodynamic therapy: clinical aspects | |
KR100564897B1 (en) | Photodynamic Therapy using Photosensitizer and Chemical Light | |
RU2300403C1 (en) | Method for treating the cases of malignant skin tumors | |
RU2310484C1 (en) | Method for treating chronic highmoritis | |
Hendrich et al. | Experimental photodynamic laser therapy for rheumatoid arthritis using photosan-3, 5-ALA-induced PPIX and BPD verteporfin in an animal model | |
RU2308992C1 (en) | Method for complex therapy of chronic highmoritis | |
Krzemien et al. | Evaluation of novel nonlaser light source for endometrial ablation using 5‐aminolevulinic acid | |
RU2162354C1 (en) | Method for treating patients suffering from chronic catarrhal gingivitis | |
RU2148424C1 (en) | Method for treating frontal and maxillary sinus diseases | |
RU2110299C1 (en) | Device for treating inflammatory diseases of perirhinal sinuses | |
Ahmad et al. | History of UV Lamps, Types | |
Radhika et al. | Photodynamic therapy for treatment of precancerous lesion | |
RU2018328C1 (en) | Method and device for curing chronic bronchitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RHINOLIGHT CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEMENY, LAJOS;BOR, ZSOLT;SZABO, GABOR;AND OTHERS;REEL/FRAME:014625/0523;SIGNING DATES FROM 20030723 TO 20030803 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |